



29(10): 29-52, 2020; Article no.IJBCRR.64238 ISSN: 2231-086X, NLM ID: 101654445

RNA Dependent RNA Polymerases of Severe Acute Respiratory Syndrome-Related Coronaviruses- An Insight into their Active Sites and Mechanism of Action

Peramachi Palanivelu^{1*}

¹Department of Molecular Microbiology, School of Biotechnology, Madurai Kamaraj University Madurai – 625 021, India.

Author's contribution

The sole author designed, analysed, interpreted and prepared the manuscript.

Article Information

DOI: 10.9734/IJBCRR/2020/v29i1030236 <u>Editor(s)</u>: (1) Dr. Chunying Li , Georgia State University, USA. (2) Dr. Varun Gupta, Albert Einstein College of Medicine, USA. (3) Mohamed Fawzy Ramadan Hassanien, Zagazig University, Egypt. (1) Antonio Carlos Pereira de Menezes Filho, Goiano Federal Institute of Goiás, Brazil. (2) Érica Tex Paulino Fundação Oswaldo Cruz (FIOCRUZ), Brazil. (3) Karen Elizabeth Campos Correa, Universidad Peruana Cayetano Heredia (UPCH), Perú. (4) Kartika Rathore, JNVU, India. (5) Ndoe Guiaro Marcellin, Institute of Medical Research And Medicinal Plants Studies, Cameroon. Complete Peer review History: <u>http://www.sdiarticle4.com/review-history/64238</u>

Original Research Article

Received 10 December 2020 Accepted 30 December 2020 Published 31 December 2020

ABSTRACT

Aim: To analyze the RNA-dependent RNA polymerases (RdRps) of Severe Acute Respiratory Syndrome (SARS)-related coronaviruses (CoVs) to find out the conserved motifs, metal binding sites and catalytic amino acids and propose a plausible mechanism of action for these enzymes, using SARS-CoV-2 RdRp as a model enzyme.

Study Design: Bioinformatics, Biochemical, Site-directed mutagenesis (SDM), X-ray crystallographic and cryo-Electron microscopic (cryo-EM) data were analyzed.

Methodology: Bioinformatics, Biochemical, Site-directed mutagenesis, X-ray crystallographic and cryo-EM data of these enzymes from RNA viral pathogens were analyzed. The advanced version of Clustal Omega was used for protein sequence analysis of the RdRps.

Results: Multiple sequence alignment (MSA) of RdRps from different SARS-related CoVs show a large number of highly conserved motifs among them. Though the RdRp from the Middle Eastern

^{*}Corresponding author: E-mail: ppmkupp@gmail.com;

Respiratory syndrome (MERS)-CoV differed in many conserved regions yet the active site regions are completely conserved. Possible catalytic regions consist of an absolutely conserved amino acid K, as in single subunit (SSU) RNA polymerases and most of the DNA dependent DNA polymerases (DdDps). The invariant 'gatekeeper/DNA template binding' YG pair that was reported in all SSU DNA dependent RNA polymerases (DdRps), prokaryotic multi-subunit (MSU) DdRps and DdDps is also highly conserved in the RdRps of SARS-CoVs. The universal metal binding motif -GDD- and an additional motif-SDD- are also found in all SARS-CoV RdRps. In stark contrast, the (-) strand RNA viral pathogens like Ebola, rabies, etc. use -GDN- rather than -GDD- for catalytic metal binding. An invariant YA pair (instead of an YG pair) is found in the primases of the SARS-CoVs. The SARS-CoVs RdRps and primases exhibit very similar active site and catalytic regions with almost same distance conservations between the template binding YG/YA pair and the catalytic K. In SARS-CoV RdRps an invariant R is placed at -5 which is shown to play a role in nucleoside triphosphate (NTP) selection and is in close agreement with SSU DdRps (viral family) and DdDps. In primases no such invariant R/K/H is found very close to the catalytic K in the downstream region, as found in RdRp and Nidovirus RdRp-Associated Nucleotidyltransferase (NiRAN) domains. An invariant YA pair is placed in the NiRAN domain instead of an YG pair, and an invariant H is placed at -5 position. Moreover, the Zn binding motif with the completely conserved Cs and a few DxD/DxxD type metal binding motifs are found in the RdRps and NiRAN domain. However, the primases contained only the DXD type metal binding motifs. **Conclusions:** The SARS and SARS-related CoV RdRps are very similar as large peptide regions are highly conserved among them. The closer identity between the RdRps of palm civet-CoV and

SARS-CoV (CoV-1) suggest their possible link as found between their spike proteins also. The invariant YG and KL pairs may play a role in template binding and catalysis in SARS-CoV RdRps as reported in DdDps. An additional invariant –YAN- motif found in SARS-CoV RdRps may play a crucial role in nucleotide discrimination.

Keywords: Coronaviruses; RNA-dependent RNA polymerases; primases; NiRAN domain; polymerase conserved motifs; active sites; catalytic mechanism.

1. INTRODUCTION

Large numbers of human and animal pathogens belong to the positive-strand RNA viruses which have been causing major global healthcare crises and unprecedented economic losses. The recent pandemic, caused by SAR-CoV-2, affected more than 72.0 million people resulting in ~1.6 million deaths worldwide. Both vaccines and antivirals have been developed at warp speed to contain the spread of the virus. Whereas the vaccines are targeted to the spike protein, the antivirals are mainly targeted to the crucial enzymes that participate in its lifecycle. One of main antivirals is against the crucial enzyme RdRp of the viruses. These RNA employ the enzyme RdRp viruses for multiplication in animal and human cells. The RdRp performs both transcription and replication processes in all these RNA viruses (except retro viruses). Therefore, RdRps have been the main target for antiviral drug development to control these RNA viruses including SARS-CoV-2. However, these efforts are hindered by limited structural information on the RdRp catalytic core and its catalytic mechanism. Though RNA viruses are highly divergent in nature, yet their key enzyme, viz. the RdRp is structurally and

functionally found to be very similar. For example, all of them are structurally similar and exhibit a characteristic cupped right-hand with three major domains, viz. Fingers, Palm and Thumb, similar to DNA polymerases and SSU RNA polymerases. Furthermore, all of them function perform the same as nucleotidyltransferases indicating inextricable relationship between structure and function among them. These viral RdRps are mostly single subunit enzymes but are associated with or part of other viral enzymes related to viral process like replication primases. methyltransferases, proofreading exonucleases, etc. Unlike SARS-CoV RdRps, many viral RdRps do not possess the proofreading activity. It is interesting to note that RdRp activity has also been demonstrated in plants, fungi and nematodes where this activity was shown to be essential for gene silencing events (cosuppression in plants, quelling in fungi and RNA interference in nematodes) [1]. An in-depth analyses and characterization of the SARS-CoV-2 genome and its proteome will pave way for the development of anti-SARS-CoV strategies including effective and safe vaccines and effective antivirals to contain the present and future pandemics.

1.1 Dynamics of Viral RNA Synthesis

Viral RdRps (EC 2.7.7.48) belong to the Main class 'Transferases' and are involved in the transfer of ribonucleoside triphosphates (NTPs) to the growing 3'–OH end of the nascent RNA chain (Fig. 1). The NTPs are added complementary to the template strand, one at a time. The overall reaction catalyzed by an RdRp may be written as,

Template RNA_n-3'OH + NTP $\xrightarrow{\text{RdRp}}$ Template RNA_{n+1}-3'OH + PP_i Mg²⁺

Fig. 1. RNA polymerization reaction by RNA polymerases

(A Mg²⁺ ion (invariably coordinated by two dicarboxalic acids, viz. D-D or D-E) binds specifically to the β - and γ -phosphates of incoming NTPs and acts as "charge shielder" and orients the α -phosphate for polymerization. The hydrolysis of P—O bond results in release of large amount of negative free energy, which is efficiently utilized in the formation of a new phosphodiester bond).

RdRps read the template RNA from $3' \rightarrow 5'$ direction and therefore, a new RNA strand is synthesized in the $5' \rightarrow 3'$ direction. RNA polymerases after successful initiation, elongate the 3'-end of the RNA by the addition of one nucleotide at a time. Unlike DNA polymerases, they can initiate a chain 'de novo' without a primer. However, some viral RdRps use an RNA or protein primer for initiation.

When they use RNA primers, they are capped at their 5'-end like the cellular mRNAs either by the RdRp associated activity or snatched from the cellular mRNAs by a 'cap snatching mechanism.'

The RNA synthesis by RdRps involves three steps, viz. initiation, elongation and termination. The newly formed RNA copies serve as blueprints for further replication and transcription processes. In general, in SARSrelated CoVs, the viral RNA is first translated into a polyprotein by the host machinery, which is subsequently cleaved by the proteases embedded in the polyprotein itself releasing the RdRp. In SARS-CoVs, the RdRp catalyzes the synthesis of the RNA genome by using the (+) RNA strand as a template to produce a complementary (-) RNA strand starting from 3'end.

1.2 Viral RNA Synthesis: Initiation, Elongation and Termination

Correct initiation of RNA synthesis is crucial for the integrity of the viral genome. These viruses are found to use two different mechanisms for initiation of viral genome replication; i) de novo or primer-independent initiation and ii) primerdependent initiation. In de novo primerindependent initiations (e.g., Flaviviruses and Noroviruses), one initiation nucleotide, usually a G at +1, provides the 3'-OH as the primer for the addition of the next nucleotide at +2, whereas the primer-dependent initiation is of two types: i) either use an oligonucleotide primer (usually synthesized by an RdRp associated primase (e.g., CoVs) or ii) a protein primer (e.g., Picornaviruses) where the 5' extremity of the viral RNA is covalently linked to an ~20 amino acid Viral Protein genome-linked peptide called VPg. In this type of initiation, a conserved Tyr-OH of the VPg is projected into the enzyme active site and thus, the initiation starts with Tyr (the Tyr-OH essentially mimics the 3'-OH for the formation of phosphodiester bond with the first nucleotide for further elongation). Protein priming can also use an invariant Ser/Thr in the VPg linked peptides [2]. Capped RNA structures, captured from cellular mRNAs by 'cap snatching' also serve to initiate replication especially in Orthomyxo- and Bunya-viruses [3,4].

For transcription process, the viral polymerase binds to the genomic RNA at the 3' non-coding leader promoter and transcribes subsequently all viral mRNAs. After successful initiation, the elongation complex takes over and completes the replication/transcription cycle. Capping (guanine-N-7 methylation) is concomitant with initiation of mRNA transcription. Polyadenylation of mRNAs occurs by a stuttering mechanism at a slipperv stop-site present at the end viral genome. By this mechanism, a U on the genomic template is copied hundreds of times at the end of viral mRNA producing a poly-(A) tail. Switching of the RdRp from transcription to the replication mode is mainly dependent on the intracellular concentrations of the nuclear capsid protein (during replication mode it ignores the transcription signals).

1.3 Error Rates and Proofreading in RdRps

Unlike the prokaryotic and eukaryotic RNA polymerases, the viral RdRps make high rate of errors ($\sim 10^{-4}$) during copying the genome. This is

mostly due to lack of proofreading activity in most of these RNA viruses. The lack of proofreading activity also favours constant creation of new genetic variants to adapt to constantly changing environmental conditions. These mutations may result in loss-of-function or gain-of-function, where both are exploited by these viruses for their successful adaptation to new environments and hosts [5]. In contrast, the RdRps of CoVs maintain their genome integrity during replication by employing an associated proofreading activity. For viruses, whose survival mainly rely on the efficient production of many progeny copies, adaptability, stability and velocity of replication are essential and these features are slowly acquired during prolonged evolutionary times by mutation and selection. As mentioned earlier, the viral polymerases are error-prone and subjected to both transition and transversion mutations. The transition mutations (purine to purine or pyramidine to pyramidine) are incorporated at a frequency of ~10⁻⁵ and transversion mutations (pyramidine to purine or vice versa) are incorporated at a frequency of 10^{-6} - 10^{-7} . The transition mutations are generated at higher frequency than transversion mutations. However, the transition mutations are less likely to result in amino acid substitutions due to "wobble" mechanism, and are therefore, more likely to persist as "silent substitutions" as single nucleotide polymorphisms (SNPs) in viral populations. However, RdRps from SARS-CoVs are associated with a proofreading mechanism and therefore, the error rates are very minimum in these viruses [6].

1.4 Basic Steps Involved in the Lifecycle of ssRNA Viruses

As viruses are non-living entities, they enter into other compatible living cells and lead a parasitic life. They are ubiquitous in nature and successfully infect all forms of life, viz. bacteria, fungi, plant and animals. Even though they infect all forms of life, they are very specific to the species they infect and hence never infect other species under normal circumstances. To survive and complete their lifecycle, they have to find the right kind of host cells which possess specific receptor(s) for them to bind and enter the cells. Generally, the viral envelope glycoprotein usually binds to the host cell receptor(s) and enters the cell through a process called endocytosis. Once they enter the cell, the fusion of the virus membrane with the host endosomal membrane releases the viral genome into the cytoplasm of host cells.

After successful entry into the host cells, the viral genome acts like host mRNA and is translated to produce the viral proteins. The translated viral proteins are of two types, viz. the structural and non-structural proteins (NSPs). They involve both in the replication of the viral genome and subsequent assembly into new viral particles and their release. In CoVs, the NSPs are first produced as a polyprotein and then cleaved by the viral endoproteases embedded on the polyprotein itself into functional proteins. One of the NSPs, viz. the RdRp makes large number of copies of the viral RNAs for viral assembly with the structural proteins. Replication takes place in the cytoplasm at the surface of endosomes. As the first step, a double stranded RNA (dsRNA) intermediate is formed from the genomic single stranded RNA. Now the dsRNA is used for providing large number of (+) ssRNA genomes. In the next step, the nuclear capsid protein covers the genomic RNAs and gets enveloped in the cytoplasm. In the final step, the new viral particles exit the cells by the budding process at the plasma membrane. Interestingly, these RNA viruses except the retro viruses complete their entire lifecycle within the cytoplasm itself. The characteristic viral reproduction number, R_{0} , is the average number of people each person with a disease can infect and it varies from virus to virus.

1.5 Nidoviruses

Viruses are broadly classified into either RNA viruses or DNA viruses depending on whether their genome is made up of an RNA or a DNA. respectively. Most of the viruses in nature are RNA viruses and use RNA genomes. For different types of RNA viruses and their classifications refer to Palanivelu [7]. The coronaviruses (CoVs) belong to Nidoviruses. The Nidoviruses are enveloped viruses with a positive, single-stranded RNA genome. The CoVs which belong to the Nidoviruses are known to have the largest genomes for RNA viruses, with their genome sizes ranging from 26 to 32 kb in length. The CoVs belong to the order Nidovirales, family Coronaviridae and subfamily Coronavirinae. (The order Nidovirales derives its name from the presence of nested 3' mRNAs as Nido is a Latin word for "nest"). The CoVs which belong to the family Coronaviridae are host specific and primarily cause enzootic infections in birds and mammals. However, in the last few decades, they have shown to be capable of infecting humans as well. The outbreak of SARS-CoV-1 in 2003, MERS-CoV in 2013 and more

recently the SARS-CoV-2 in 2020 has demonstrated their adaptability and lethality when they cross the species barrier and infect humans. Based on genetic and antigenic criteria, the CoVs have been classified into four groups: α -, β -, γ - and δ -CoVs. It is interesting to note that most of the CoVs are not dangerous to humans. For example, out of 7 family members, only 3 (SARS-CoV-1, MERS-CoV and SARS-CoV-2) caused SARS in epidemic and pandemic proportions and all the three belong to β genus. The other 4 human coronaviruses (HCoV-OC43 (β), HCoV-HKU1 (β), HCoV-229E (α), and HCoV-NL63 (a)) cause most of the colds during the year but they are not a serious threat to healthy individuals. In this communication, only the SARS and SARS-related CoVs and their replication machinery with special reference to SARS-CoV-2 are discussed.

1.6 Genome Organization of SARS-CoVs

- 1. The genome size of CoVs ranges from 26 to 32 kb. The genome contains a 5' cap structure and a 3' poly-(A) tail, allowing it directly to act as an mRNA for translation in host cells. They are enveloped viruses and the RNA genome is covered by a nuclear capsid protein with helical symmetry. Coronaviruses are roughly spherical with surface proteins, viz. the spike, envelope and membrane proteins projecting from the membrane.
- 2. The viral genome is a non-segmented, positive-sense, single-stranded RNA.
- 3. The 5' end of the genome invariably contains an untranslated region (5'-UTR) which is known to form multiple stem-loop structures required for transcription and replication of the RNA. In addition to, in all Nidoviruses the genomic and sub-genomic RNAs share a common 5' leader sequence.
- The 3' end of the genome also contains an untranslated region (3'-UTR) which is also known to form RNA secondary structures required for replication and synthesis of viral RNA.
- The CoV genomes are organized as: 5'Cap—5'-UTR→ORFs 1a and 1b→S (Spike protein)→E (Envelope protein)→M (Membrane protein)→NCP (nuclear capsid protein) →3'-UTR-pol-(A) tail with accessory protein genes interspersed within the structural protein genes at the 3' end of the genome (Fig. 2).

- The main ORFs 1a and 1b encode the NSPs and occupy two-thirds, ~20 kb of the viral genome, as opposed to the structural and accessory proteins, which take up only ~10 kb of the genome.
- 7. The CoV genomes contain two overlapping reading frames ORF 1a and 1b, which direct the synthesis of two precursor polyproteins. (The expression of ORF1b occurs by a ribosomal frame-shift the ORF1a/ORF1b mechanism as overlapping nucleotide sequence is shown to be capable of inducing ribosomal frameshift both in vitro and in vivo. In other words, the 1b is translated by a -1 frameshift mechanism involving a pseudoknot structure). ORFs 1a and 1b encode 16 non-structural proteins and are highly conserved throughout CoVs.
- The ORFs 1a and 1b NSPs are produced as a polyprotein and the polyprotein selfcleaves to form 16 NSPs (NSP1–NSP16) [8].
- 9. The sub-genomic RNA produce rest of the 4 essential structural proteins, viz. S, E, M, and NCP. Interspersed between these main structural gene reading frames, are the internal reading frames for the accessory proteins. The number of accessory proteins and their function is unique depending on the type of CoV (Fig. 2). The structural proteins like the NSPs also share common features in all CoVs [8].
- The accessory proteins are almost exclusively nonessential for replication of the genome but some of them have been shown to be required for viral pathogenesis [9].

ORFs 1a and 1b genes encode 16 non-structural proteins (NSP1–11 and NSP12-16, respectively).

The structural genes encode the structural proteins, viz., S, E, M and NCP.

The accessory genes (shown in red) are unique to different CoVs in terms of number, organization, sequence, and function [10]. Some of them are embedded in the main structural protein genes as internal ORFs.

Typical UTRs for β -coronaviruses are 265 nt at the 5' end and 229 nt at the 3' end of the RNA. In SARS-CoV-2, the 5'- and 3'-UTRs are 265 and 358 nucleotides long, respectively [8].




Fig. 2. A schematic diagram of the genome organization of COVs

1.7 Production of Polyprotein and Polyprotein Processing in CoVs

The ORFs 1a and 1b are translated as polyproteins and then processed by the viral proteases. This strategy is used by many viruses to ensure production of all the essential proteins for completing the lifecycle at one-go. These polyproteins thus, produced are subsequently cleaved into individual proteins by the viral proteases embedded on the polyprotein itself. For polyprotein processing, the CoVs harbour two or three protease genes (usually of different types) in its genome to cleave the polyprotein (CoVs do not depend on the host proteases for their polyprotein processing). These are the papain-like proteases (PLpro), encoded within nsp3, and a serine-type of protease, (Mpro) also known as the main protease encoded by nsp5. Most of the CoVs encode two PLpros within nsp3, except the β-CoVs like SARS-CoVs and MERS-CoV, where they produce only one PLpro. The PLpro cleaves NSP1/2, NSP2/3, and NSP3/4 boundaries, whereas the Mpro cleaves The replication-transcription is the rest. accomplished by the membrane-bound replicase-transcriptase complex (RTC). The RTC is composed of by a few proteins from the processed polyproteins. The NSPs and their proposed functions are discussed elsewhere.

1.8 Characteristics of the NSPs, Structural and Accessory Proteins

1.8.1 NSPs and their functions

ORF-1a: (NSPs1-11)

NSP1*: Suppresses antiviral host responses by blocking host-cell translation and promoting cellular mRNA degradation, which results in suppressing the host innate immune responses. This is achieved by the NSP1 by associating strongly with 40S ribosomal subunit and shutting-down the host mRNA translation both *in vitro* and *in vivo*. Furthermore, its binding to the ribosome also leads to endonucleolytic cleavage and subsequent degradation of host mRNAs. (However, interactions between the NSP1 and a conserved region in the 5'-UTR of viral mRNA prevent shutdown of viral protein expression through an unknown mechanism) [11].

NSP2: Unknown Function

NSP3: Multi Domain Region*

NSP4 and NSP6: are transmembrane proteins which form double-membrane vesicles (DMVs) from the virus-induced network of host endoplasmic reticulum membranes; also known as viral replication organelle. (The DMVs offer favourable microenvironment for viral RNA synthesis and also protect the double-stranded replicative forms from innate immune sensors that are activated by doublestranded RNAs). The newly synthesized RNAs, single-stranded forms, are exported to the cytosol for translation and viral genome assembly through the molecular pores of DMVs [12].

NSP5: Mpro (Main protease or CL protease) **NSP6:** Type I IFN antagonist; suppresses the induction of both IFN as well as the IFN signaling pathways.

NSP7: Complex with NSP8 Primase for functional RTC

NSP8: Primase (NSP7 and NSP8 are known to make a hexadecameric complex that function as an effective primase to synthesize primers for the NSP12 RNA polymerase).

NSP9: ssRNA Binding Protein

NSP10: Stimulates NSP14 and NSP16 activities and thus, involves in cap and 2'-*O*-methylaton activities

NSP11: A short peptide at the end of 1a [8].

*The multi-domain NSP3 is the largest protein encoded by the CoV genome, with an average molecular mass of ~200 kDa. At different domains least. nine are characterized in the NSP3 of all known CoVs. These regions are as follows: (Fig.1). UBI1, Ubiquitin-like 1 domain; HVR-ARD, hyper variable Acid (Glu)-Rich Domain; X domain; SUD, SARS-CoV Unique domain; UBI-2, Ubiquitin-like 2 domain; PL2pro, Papain-like protease domain (releases NSP1, 2 and 3); NAB, Nucleic acid binding zinc-finger domain; TMD, Transmembrane domains1 & 2; Y, Y-Domain, highly conserved in all Nidoviruses [13].

ORF-1b: (NSPs 12-16)

NSP12: RdRp, activated by NSP8 and NSP7 complex of ORF1a

NSP13: Helicase (RNA unwinding enzyme with $5\rightarrow 3'$ polarity). NSP12 and NSP13 are expressed as part of two different cleavage products residing next to each other in ORF-1b in all Nidoviruses. The helicase is multifunctional and is implicated in transcription, replication, translation and virion biogenesis.

NSP14: ExoN, is a multifunctional protein. It possesses both N7-guanine methyltransferase (MTase) and exonuclease proofreading activities. The N7-guanine MTase adds 5'-Cap to the viral mRNAs and the $3'\rightarrow 5'$ exonuclease acts as the proofreader for RdRp.

NSP15*: NendoU (a Uridine-specific endoribonuclease, chops-up leftover viral RNAs so that to hide it from the infected cell's antiviral defenses*).

*Type-I interferon I (IFN-1) induction and signaling represents one of the major innate antiviral defense pathways in humans, ultimately leading to the induction of several hundred antiviral interferon-stimulated genes (ISGs). SARS-CoV infections are first sensed by retinoic acid-inducible gene-I (RIG-I). The RIG-1 is nothing but a cytosolic pattern recognition receptor (PRR) which is responsible for the activation of the IFN-1 mediated host defense system [11,14].

(Interestingly, the ribonucleases, NSP14 and NSP15 are unique to the *Nidovirales* and are hence considered as genetic markers for these viruses).

NSP16: a 2'-O-ribose methyltransferase, essential for 5'-end cap modification to evade host immune system and also implicated in translation efficiency of viral mRNAs [8].

1.8.2 Structural proteins and their functions in CoVs

The viral envelope is made up of a lipid bilayer in which the surface proteins S, M and E are anchored in the ratio of $E:S:M \sim 1:20:300$.

The spike protein (~150 kDa, 1273 amino acids), is a heavily glycosylated protein (mainly with N-linked glycosylations). It assembles into a homotrimer and forms the distinctive spike-like structures on the surface of the virus (Analyzed in detail in my earlier communication [7].

The membrane protein (~25 kDa, 222 amino acids) is the most abundant structural protein found on the viral envelope and is also glycosylated. It is a smaller protein with three transmembrane domains and plays a central role in virus morphogenesis and assembly via its interactions with other viral proteins. It is also known to involve in the budding process of CoVs during viral exit from the host cells. It is interesting to note that the CoV-2 sequence shows remarkable similarity (98% identity) to the sequences from bat and pangolin isolates [15].

The envelope protein (~8 kDa, 75 amino acids) is the smallest one and also found in small quantities in the viral envelope. The E protein is highly conserved in CoVs. It is known to facilitate the viral assembly and release. It self-assembles and functions as a viroporins, forming pentameric protein-lipid pores on host membranes to allow ion transport. It also plays a role in the induction apoptosis. Interestingly, sequence of comparisons show that the CoV-2 envelope protein is almost identical to the sequences from bat and pangolin CoVs [15].

The nuclear-capsid protein (~46 kDa, 419 amino acids) forms the nuclear capsid. It oligomerizes to form a closed capsule-like structure, inside which the genome is securely packed. The nuclear capsid binds the viral genome as beads-on-a-string type conformation. It is composed of two separate domains, an N-terminal domain and a Cterminal domain which are separated by a linker region. The NCP is also heavily phosphorylated, and phosphorylation of NCP has been suggested to trigger a structural change enhancing its affinity for viral versus nonviral RNAs. The usual N-terminal Met is removed and the new Ser at the N-terminal is acetylated. It plays a fundamental role during virion assembly through its interactions with the viral genome and the membrane protein M. It also plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication. NCP is found to be the major antigen recognized by convalescent antisera, suggesting its potential as a diagnostic tool or for vaccine development [10].

1.8.3 Accessory proteins (APs): Their organization and functions in SARS-CoVs

The SARS-CoV-2 produces as many as 27 proteins/peptides out of which 16 of them are NSPs, 5 of them are structural proteins and 7 of them are accessory proteins (APs). The number and their arrangements of APs differ in different groups of CoVs like α , β , γ and δ . The APs of the three of the β -CoVs which caused the pandemics are only shown here (Fig. 3). Functions of the APs are outlined below [8].

The **ORF3a AP** makes a hole in the membrane of infected cells to make it easier for the new viruses to escape. It also triggers inflammation, one of the most dangerous symptoms of COVID-19.

The **ORF3b AP** is a novel short putative protein with 4 helices. The CoV-2 AP exhibits no homology to the existing SARS-CoVs or SARSrelated-CoVs. However, the ORF3b still possessed Interferon (IFN) antagonist and Interferon Regulating transcription Factor-3 modulating activities, suggesting a potential link between SARS-related-CoVs from bats. [8]. The **ORF6 AP** blocks the signals send out to the immune system by the infected cells.

The **ORF7a AP** might be used to cut-down an infected cell's supply of tetherin (viral trapping mechanism of the host cells), allowing more of the viruses to escape. It also contributes to viral pathogenesis *in vivo* by inducing inflammatory responses (cytokine storm) in SARS and may also contribute to viral-induced caspase-3-dependent apoptosis.

The **ORF7b AP** is ~5 kDa integral membrane protein, localized to the Golgi compartment in SARS-CoV-infected cells.


The ORF8 AP's function is not clear yet.

The **ORF9b AP** blocks IFNs, the body's key molecules which involve in first-line of defense against viruses.

The **ORF9c** overlaps the same stretch of ORF9b RNA, but with no known function [16].

1.8.4 Basic Structural Features of RdRps in CoVs

In general, the viral RdRps are structurally and functionally similar including that of the SARS-CoVs. For example, all of them exhibit a characteristic cupped right hand with three major domains, viz. Fingers, Palm and Thumb, which is similar to DNA polymerases and SSU RNA polymerases. In CoV-2, amino acids from 398 to 580 form the fingers domain, 581-812 form the palm domain including an interface of ~60 amino acids and 813-932 form the thumb domain. Amino acids 1-250 of the N-terminal region form the Nidovirus RdRp-Associated Nucleotidyltransferase (NiRAN) domain. The NSP7 and NSP8 are also known to interact with the NiRAN domain. Fig. 4 shows the arrangement of the various domains of the SARS-CoV-2 RdRp.





The four structural proteins are shown as green boxes and the accessory proteins as yellow boxes. Upper ones show the overlapping / internal ORFs



Fig. 4. A schematic diagram showing different domains of the SARS-CoV-2 RdRp

(The NiRAN domain is found in all COVs including the SARS-CoVs. The RdRp folds in such a way where the NiRAN domain encircles the active site). Adapted from Hillen et al [17]

1.8.5 RdRp form a Replicase–Transcriptase Complex (RTC)

For viruses, whose survival must rely on the efficient production of many progeny copies, stability, velocity and fidelity of replication essential, and these are features are constantly evolved and perfected during prolonged evolutionary times. The lifecycle of RNA viruses mainly depends on the successful transcription and replication to make all the essential structural and NSPs and viral genomes to infect more and more cells. Interestingly, in RNA viruses both replication and transcription are performed by the same enzyme, viz. the RdRp and both the processes are biochemically equivalent, often catalyzed by a multienzyme complex known as RTC. In CoVs, the replication complex is yet to be characterized in sufficient details both in vitro and in vivo. The multienzyme RTC is known to be composed of the RdRp (NSP12), the primase complex (NSP7 and NSP8) and other associated helicase. enzymes like proofreading exonuclease, methyltransferase, etc. The key component of the RTC complex is the RdRp, which catalyzes the synthesis of viral RNA and thus, plays a central role both in the replication and transcription cycle of all CoVs. Using biochemical assays and reverse genetics, Subissia et al [18] have studied the important conserved residues in NSP7, NSP8 and NSP12. They found that even though several NSP7 mutations affected virus replication to a limited extent, the two NSP8 mutations involving residues P^{183} and R^{190} were found to be essential for interactions with NSP12. Furthermore, a third mutation involving K^{58} was found to be critical for the interaction of the polymerase complex with RNA. All three mutations were found to lethal to the virus [18]. Besides, without a loss of processivity, the NSP7/NSP8/NSP12 complex can associate with NSP14, a bifunctional enzyme. possessing both the 3'-5' exoribonuclease and RNA capping N7-guanine methyltransferase activities which are essential for replication fidelity and 5'-RNA capping [18-20].

1.8.6 RdRps and direct-acting antiviral drugs

RNA viruses, except the retro viruses, complete their entire life cycle within the cytoplasm itself and are able to exploit the host machineries for this purpose. At least 4 critical stages are found in their lifecycle. These 4 crucial stages in their lifecycle are the main targets to design directacting antiviral drugs (DAADs) to block each of these steps. At least 5 different types of DAADs are developed to block the viruses at each stage of their lifecycle [21], viz. i) Protease Inhibitors, ii) RdRp Inhibitors, iii) Interferon-Resisting Protein Glycosylation Inhibitors, Inhibitors, iv) V) Antioxidant Inhibitors. Only the inhibitors for the RdRp are elaborated further. As discussed elsewhere, the crucial step in the multiplication of these viruses is the transcription and replication processes which are essentially executed by the enzyme RdRp. A substantial obstacle for the discovery, optimization, and comprehensive evaluation of effective nucleotide based drugs for the SARS-CoV-2 is the lack of molecular details on the active sites, substrate recognition and catalytic mechanism during replication. Even though, no new inhibitors are designed for this CoV-2 RdRp, some of the broad-spectrum drugs designed for other RdRps are repurposed to block the RdRp of CoV-2 also. Some well-known examples are the broad-spectrum nucleoside analog inhibitors like Remdesivir (Ebola virus), Favipiravir (Influenza viruses), Ribavirin (Hepatitis C virus, HCV), Sofosbuvir (HCV), Galidesivir (HCV), Penciclovir (Herpesvirus), etc. These pro-drugs require efficient intracellular activation to their respective triphosphate forms to participate in the polymerization reactions. Therefore, it depends not only on their efficient conversion into their active forms in viral infected patients but also their availability in high concentrations to compete with the natural substrates. Secondly, the efficacy of these nucleoside analogues depends on their effective binding onto the active sites of CoV-2 RdRps for successful incorporation to block the RNA synthesis. Thirdly, unlike most of the RNA viruses, the CoVs also possess a proofreading activity.

Therefore, this communication, analyses the RTC of the SARS and SARS-related CoVs and their catalytic sites, metal binding sites and catalytic mechanism with special reference to CoV-2 RdRp.

2. MATERIALS AND METHODS

A large number of RdRp sequences of SARS and SARS-related CoVs are available in PUBMED and SWISS-PROT databases. For MSA analysis of various RdRps, the sequences were retrieved from SWISS-PROT and PUBMED sites and analyzed using Clustal Omega tool, an accurate, fast and widely accepted algorithm, available on their website. This communication presents the results obtained from the protein sequence analysis of these enzymes which are further supported by biochemical, SDM experimental data and X-ray crystallographic and cryo-EM studies of the SARS-CoV-2 RdRp and other related RdRps from positive and negative strand RNA viral pathogens available in the literature. The CoV-2 RdRp is used as the model enzyme for delineating the polymerization mechanism based on the above data.

3. RESULTS AND DISCUSSION

3.1 Analyses of Active Site Regions of RdRps of SARS-CoVs

Figure 5 shows the MSA analysis of the RdRps of SARS-related CoVs including SARS-CoV-2. The RNA polymerase sequences from different CoVs reveal conservation of large peptide regions among them. The MERS-CoV RdRp sequence varies in many places but completely conserved in the crucial catalytic regions. Besides, a three-amino acid deletion at the Nterminal region is seen in all except MERS-CoV RdRp (Fig. 5). The catalytic region and catalytic amino acid of the CoV-2 RdRps were arrived at from the MSA and cryo-EM data [17], and also from the data already available on other RdRps, DdRps and DNA polymerases [22-26]. The prokaryotic and eukaryotic multi-subunit (MSU) DdRp catalytic subunits invariably use the catalytic amino acid R followed by an invariant Y/FG (except human RNA polymerase where it uses a KG) whereas the single subunit (SSU) RNA polymerases and DNA polymerases mostly use the catalytic amino acid K followed by an invariant YG pair (Table 1). MSA analysis of the SARS and SARS-related CoVs uses an invariant K which is followed by the invariant YG pair where the invariant K could be possibly the catalytic amino acid as in DdDps (Table 1). The

YG which is commonly found in all these nucleic acid polymerases is implicated in template binding [22-25]. Wang et al. [2] investigated the molecular basis of SARS-CoV-2 RNA replication by analyzing the cryo-EM structures of the stalled post-translocated preand polymerase complexes. They found in the pre-translocated complex, N496, K500, S501, N507, and K577 from the fingers domain and Y595 from the palm domain directly participate in stabilizing the phosphate backbone of the template. Interestingly, the same Y595 is in fact, part of the invariant YG pair (highlighted in yellow) found in all SARS-CoVs RdRp (Fig. 5) These findings were further corroborated by cryo-EM analysis of the RdRp of CoV-2 by Hillen et al [17], where they have also shown that the Y595 in the palm domain of the CoV-2 RdRp. However, in primases (NSP8) an invariant YA pair is identified as the probable template binding pair in the SARS-related CoVs and the K as the probable catalytic amino acid as in the RdRps (Fig. 6). The possible metal (Mg²⁺) binding motifs in the RdRps are highlighted in light green. The Zn² binding motif (CxxCxxxxC-) highlighted in orange suggesting that like other RNA polymerases this enzyme also could be a Zn metalloenzyme.

One of the most conserved universal motifs of all the RdRps is the -GDD- and is shown to be essential for the catalytic function of RdRps [27,28]. This motif is also found (-G⁸²³DD- in the thumb region) in CoV and CoV-related RdRps. In the secondary structure analysis of -GDDmotif, the G is found to involve in a tight turn and modifying this $G \rightarrow A$ by SDM experiments completely abolished the RdRp activity in Encephalomyocarditis virus [29]. The functional role of G in the -GDD- motif was further confirmed by similar SDM experiments in the replicase of a plus-strand RNA viruses like the $Q\beta$ bacteriophage and polio virus (PV). The substitution of the G of the -GDD- sequence by C. M, P or V residues inactivated the enzyme activity completely [30,31]. Additional conserved metal binding motif, viz. -ADD- is commonly found in many (+) strand viral pathogens. dengue viral RdRp crystals soaked in 0.2 M MgCl₂ clearly revealed the presence of one hydrated Mg²⁺ ion close to the expected catalytic position, hexa-coordinated by Asp-533 of -ADD⁵³³- (motif A) via a water molecule and by Asp-664 of -GDD⁶⁶⁴⁻ (motif C). Interestingly, the -ADD- and -GDDmotifs are also completely observed in the RdRps of Yellow Fever, Japanese Encephalitis and West Nile viruses [32]. These two motifs (- A/SDD- and –GDD-) are also found in SARS-CoV RdRps as well. The invariant $-S^{759}$ DD- motif is located in the active site palm region of SARS-CoV-2 RdRp [17], which may be equivalent to the –ADD- motif of other viral RdRp as discussed above and participates in binding to the Mg²⁺ ion (Fig. 5).

Lehman et al. [33] have shown that the NiRAN domain which is unique to the CoVs is shown to exhibit nuceotidtyl-transferase activity [33]. Furthermore, they have also suggested K^{73} (marked in red) could be in the active site of the NiRAN domain as the $K^{73} \rightarrow A$ mutation dramatically reduced the viral titre. In addition to, K^{73} they also found $R^{116\rightarrow}A$, $K^{103\rightarrow}A$, $D^{126\rightarrow}A$, $D^{218\rightarrow}A$ mutations (highlighted in green) reduced the viral titre markedly suggesting that they may also possibly in the active site region of the NiRAN domain. The D¹²⁶ and D²¹⁸ are found in catalytic regions by MSA analysis also. However, a template binding YA pair as in primases (NSP8) preceded by an invariant proton acceptor R and an NTP binding basic amino acid H at -5 are found in this domain and highlighted in yellow. Interestingly, an invariant YAN motif (highlighted in yellow) which is shown to be involved in NTP selection in CoV-2 RdRp by binding to the 2-OH of the NTP is also found. They [17,2] have also found this motif is completely conserved in all SARS-related CoV RdRps (except in MERS-CoV RdRp). In addition to, the Mg²⁺ binding –DxD- and -D²¹⁸XXD- motifs are also identified in this NIRAN domain by MSA analysis and are highlighted in green.

As mentioned in my earlier communication on spike proteins [7] the SARS-CoV-1 and civet-CoV exhibit very close sequence identity to each other in many places in RdRps and primases (highlighted in magenta), further confirming the observation that the civet-CoV could be a possible intermediate for SARS-CoV-1.

3.2 Analysis of the Primases of the RTC of SARS-CoVs

It has been shown that the RdRps of SARS-CoVs are a primer-dependent enzyme and it forms the holoenzyme by complexing with the primase subunit NSP8 and an associated protein NSP7 [8,17,19].

Figure 6 shows the MSA analysis of the primase enzyme in SARS and SARS-related CoVs. There is no universal –GDD- motif in primases as found in all (+) strand RdRps. However, other DxD type metal binding motifs which could bind the Mg²⁺ at the catalytic site is found and highlighted in green. Instead of a regular -YG- template binding pair, a YA pair is found (highlighted in yellow). Except in MERS-CoV RdRp, all the other SARS and SARS-related CoV primases show the -YA- pair with an S as -YAS- which is also found in SSU DdRps as -YGS-. [23]. In fact, the S in the -YGS- is shown to be essential for nucleotide discrimination in SSU RNA polymerases. In SSU RNA polymerases, the invariant S with the YG pair (e.g., T7 RNAP in Table 2) is shown to be important in nucleotide discrimination. It is interesting to note, that a single mutation modifying the S in -YGS- to A by a SDM experiment, the RNA polymerase behaved like a DNA polymerase, accepting dNTPs, suggesting that Ser-OH might involve in nucleotide discrimination by binding to the 2'-OH of the incoming NTPs [34,23]. The amino acid K in the invariant KL (marked in red) is predicted to play the catalytic role in the polymerization process as in RdRps. It is interesting to note that the invariant KL and YG pairs are common catalytic diads in eukaryotic DNA polymerases too (Table 1) [23].

The function of NSP8 as a primase in SARS-CoVs has been further proved unequivocally by Imbert et al [35]. They found that the primase synthesized de novo up to 6 nucleotides in a sequence-specific manner which could be subsequently used as a primer for RdRp for RNA synthesis [35,36]. It is interesting to note that Imbert et al. [35] have also shown that the NSP8 uniquely encode a Mn²⁺ dependent, rifampicin insensitive, second RdRp in SARS-CoVs but with relatively with low fidelity which closely agrees with the MSA findings (in fact, it lacks an NTP binding R at -5 from the catalytic pair KL, which is found in the high fidelity RdRps). They also suggested that the RdRps and primases in SARS-CoVs might have a possible common origin which is also supported by the MSA analysis (Table 1). The SARS-CoV primases revealed marked sequence preferences like cellular primases where RNA synthesis starts with a purine, viz. G or A. Furthermore, GTP analogues such as 3'-dGTP efficiently inhibited primase activity suggesting the primases as an attractive antiviral target for SARS-CoVs. The primase activity was most sensitive to replacement of either of the three residues, viz. $K^{58} \rightarrow A$, $K^{82} \rightarrow A$ and $S^{85} \rightarrow A$. Subissi et al. [37] have also shown by SDM experiments that K^{58} (marked in red) in the highly conserved block is crucial for the assembly of the primase with

RdRp as the conversion of K→A affects not only the assembly but also RNA synthesis [37]. It is known that NSP8 and NSP7 confer processivity to the RdRps and hence the mutation at K⁵⁸ was found to be lethal for the SARS-CoV RdRps [37]. Subissi et al. [37] also found that the replacement of two more NSP8 residues (P¹⁸³ and R¹⁹⁰ at the C-terminal end, marked in red) were essential for interaction with RdRp (NSP12) and a third amino acid residue K⁵⁸ was critical for the interaction of the polymerase complex and with RNA and therefore, all the three amino acid modifications were found to be lethal to the virus. Cryo-EM studies have shown that the CoV-2RdRp was bound to a heterodimer of NSP7 and NSP8 as well as to a second subunit of NSP8. The binding site for the NSP7-NSP8 heterodimer was found to be well conserved and overlapped with the conserved regions of polymerase functional domains (fingers and thumb) and all three subunits are essential for RNA synthesis [17].

CLUSTAL O (1.2.4) MSA of SARS-related CoVs' RdRps

SABAS-COV-1 SADASTFENNOCC-USAALTPCCTCT EPUVYRAEDIXNEKVAGFARFLENNOCCRO 57 Pangolin-CoV SADASTFENNOCG-USAALTPCGTCT EPUVYRAEDIXNEKVAGFARFLENNOCCRO 57 SABAS-CAV-2 SADASEFLENNOCG-USAALTPCGTCT EPUVYRAEDIXNEKVAGFARFLENNOCCRO 57 Bat_BarG13-CoV SADASEFLENNOCG-USAALTPCGTCT EPUVYRAEDIXNEKVAGFARFLENNOCCRO 57 SABAS-CAV-2 SADASEFLENNOCG-USAALTPCGTCT EPUVYRAEDIXNEKVAGFARFLENNOCCRO 57 Bat_BarG13-CoV SADASEFLENNOCG-USAALTPCGTCT EPUVYRAEDIXNEKVAGFARFLENNOCCRO 57 SABAS-CAV-1 ELDDQGHLL BYFVVRHMYSENVELEKKEDDLLROCDAVAHDFETF EFUVKRTER USD 117 FARS-COV ELDDQGHLD BYFVVRHMYSENVELEKKEDDLLROCDAVAHDFETF EFUVKRTER USD 117 BARS-COV-2 ENDEDDNLL DSTFVVRHMYSENVELEKTENDEETINLKOCPAVAHDFETFETFUKTURFET USD 117 BARS-COV-2 ENDEDDNLL DSTFVVRHMYSENVELEKTENDEETINLKOCPAVAHDFETFETFUKTURFET USD 117 BARS-COV-2 ENDEDDNLL DSTFVVRHMYSENVELEKTURCERTANDERTINLKOCPAVAHDFETFETFUKTURFET USD 117 BARS-COV-2 ENDEDDNLL DSTFVVRHMYSENVELEKTURCERTANDERTINLKOCPAVAHDFETFETFUKTURFET USD 117 ROBEDDNLL DSTFVVRHMYSENVELEKTURCERTANDERTINLKOCPAVAHDFETFETFUKTURFET USD 117 RARS-COV-1 TFYTMDLV ALRHFETSGNOTTKELLTYNNCODDYFENKDYPENENDILKVL NI BARS-COV-1 TFYTMDLV ALRHFETSGNOTTKELLTYNNCODDYFENKDYPENENDILKVL NI RARS-COV-1 TFYTMDLV ALRHFETSGNOTTKELLTYNNCODDYFENKDYPENENDILKVL NI RARS-COV-1 <th>MERS-CoV</th> <th>-SKDSNFLNRVRGSIVNARIEPCSSGL<mark>STDVVFRAFD</mark>CNYKAKVAGIGKYYKTNTCRFV</th> <th>59</th>	MERS-CoV	-SKDSNFLNRVRGSIVNARIEPCSSGL <mark>STDVVFRAFD</mark> C NY KAKVAGIGKYYKTNTCRFV	59
Pangolin-CoV SADASSLINEVCO-VSAARLPPCGTOT FUDVYRAPDI YNDRVAGERKELKENCORPO 57 SADASSLINVCO-VSAARLPPCGTOT FUDVYRAPDI YNDRVAGERKELKENCORPO 58 SADASSLINVCO-VSAARLPPCGTOT FUDVYRAPDI YNDRVAGERKELKENCORPO SARS-COV-2 SADASSLINVCO-VSAARLPPCGTOT FUDVYRAPDI YNDRVAGERKELKEND SARS-COV-1 SARS-COV-1 SARS-COV-2 SITEYTMADIA' ALKHET CONSULATION CONDENTING FUDVER FULLOW FUT SARS-COV-2 SITEYTMADIA' ALKHET CONCOLLKELLVTNNCCDDDYFNERDYDLENVAR SARS-COV-1 SITEYTMADIA' ALKHET CONCOLLKELLVTNNCCDDDYFNERDYDLENVAR SARS-COV-1 SITEYTMADIA' ALKHET CONCOLLKELLVTNNCCDDDYFNERDYDLENVAR SARS-COV-1 SITEYTMADIA' ALKHET CONCOLLKELLVTNNCCDDDYFNERDYDLENVAR SARS-COV-1 SITEYTMADIA' ALKHET CONCOLLKELLVTNNCCDDDYFNERDYDLENVAR SARS-COV-1 SITEYTMADIA' ALKHET CONCOLLKELLVTNNCCDDDYFNERDYDLENVAR SARS-COV-1 SITEYTMADIA' ALKHET CONCOLLKELLVTNNCCDDDYFNERDYDDYFNERDILLVYAR SARS-COV-1 SITEYTMADIA' ALKHET CONCOLLKELLVTNNCCDDDYFNERDYDDYFNERDILLVYAR SARS-COV-1 SITEYTMADIA' ALKHET CONCOLLKELLVTNNCCDDDYFNERDYDDYFNERDILLVYAR SARS-COV-1 SITEYTMADIA' ALKHET CONCOLLKELLVTNNCCDDDYFNERDYFNERDYDDYFNS SARS-COV-2 SILVELCOV SITEYTMADIA' ALKHET CONCOLLKEL			
BARB-CoV-2 SADAGSFLARVCG-VSAARLPPGGTGTTDVVYRAPTIDEVAGEARFLEXINGCEPG 57 Bat_RaTG13-CoV SADAGSFLARVCG-VSAARLPPGGTGTTDVVYRAPTIDEVAGEARFLEXINGCEPG 57 MERS-CoV SADAGSFLARVCG-VSAARLPPGGTGTTDVVYRAPTIDEVAGEARFLEXINGCEPG 57 MERS-CoV ELDDQGHHLDSYFVVRHTMENVELEKHCYDLLRDCDAVAPHDFFTFV-UNDVRCEPG 57 MERS-CoV ELDDQGHHLDSYFVVRHTMENVELEKHCYDLLRDCDAVAPHDFFTFVURUKTF 117 SARS-CoV-1 ENDEGKLLDSYFVVRHTMENVGEHETYNLVKDCPAAAHDFFFFRIGODVFLSD 117 SARS-COV-2 ENDEDGKLLDSYFVVRHTMENVGEHETYNLVKDCPAAAHDFFFFRIGODVFLSD 117 SARS-COV-2 ENDEDGKLLDSYFVVRHTMENVGEHETYNLKDCPAAAHDFFFFRIGODVFLSD 117 SARS-COV-2 ENDEDGKLLDSYFVVRHTMENVGEHETYNLKDCPAAAHDFFFFRIGODVFLSD 117 SARS-COV-1 ENDEDGKLLDSYFVVRHTMENVGEHETYNLKDCPAAAHDFFFFRIGODVFLSD 117 SARS-COV-1 ENDEDGKLLDSYFVVRHTMENVGEHETYNLKDCPAAAHDFFFFRIGODVFDIST 117 SARS-COV-1 ENDEDGKLLDSYFVVRHTMENVGEHETYNLKDCPAAAHDFFFFRIGOTVFDIST 117 SARS-COV-1 ENTEYTMENUTY LRHPDONCOTLKELUTYNCCDDDFFNKKDUTDFVENDIST 117 SARS-COV-1 ENTEYTMADUT LRHPDONCOTLKELUTYNCCDDDFFNKKDUTDFVENDIST 117 SARS-COV-1 ENTEYTMADUT LRHPDONCOTLKELUTYNCCDD		~	•
Wuhan_Std CoV-2 SADAGSFLINKUG-VSAARLTPCGTGT DTUVVRAFDIYNDRVAGFAKFLKTNCCFP0 57 Bat_RaTG13-CoV SADAGSFLINKUG-VSAARLTPCGTGT DTUVVRAFDIYNDRVAGFAKFLKTNCCFP0 57 MERS-CoV ELDDQGHHLDSYFVVKRHTMENYELEKHCYDLLRDCDAVAHDDF FFV UCHTPY LTSD 117 SARS-CoV-1 ENDEGKLIDSYFVVKRHTMENYELEKHCYDLLRDCDAVAHDDF FFV UCHTPY LTSD 117 Pangolin-CoV EKDEDKLIDSYFVVKRHTMENYELEKHCYDLLRDCDAVAHDDF FFV UCHTPY LTSD 117 SARS-CoV-2 EKDEDKLIDSYFVVKRHTMENYGHEETINLKDCPAVAKHDFFKFRIDGDVP LTSD 117 BARS-CoV-2 EKDEDKNLIDSYFVVKRHTFSNYQHEETINLLKDCPAVAKHDFFKFRIDGDVP LTSD 117 Bargard13-CoV EKDEDKNLIDSYFVVKRHTFSNYQHEETINNLLKDCPAVAKHDFFKFRIDGVP LTSD 117 Bargard13-CoV EKDEDKNLIDSYFVVKRHTFSNYQHEETINNLLKDCPAVAKHDFFKFRIDGVP LTSD 117 MERS-CoV EKDEDKNLIDSYFVVKRHTFSNYQHEETINNLLKDCPAVAKHDFFKFRIDGVP LTSD 117 SARS-CoV-1 EITYTMADLY A.RHFEGKOTTKELLYTNCCDDDYFNKLWDFPFKRVKDWP LTSV 117 SARS-CoV-2 EITYTMADLY A.RHFEGKOTTKELLYTNCCDDDYFNKLWDFPFFKRVKDWD LTSV 177 SARS-CoV-1 EITKYTMADLY A.RHFEGKOTTKELLYTNCCDDDYFNKLWDYDVENPEJLKVKAH 177 SARS-CoV-2 EITKYTMADLY A.RHFEGKOTTKELLYTNCCDDDYFNKLWDYDVENPEJLKVKAH 177 BARS-COV-1 EITKYTMADLY A.RHFEGKOTTKELLYTNCCDDDYFNKLWDYDVEN			
Bat_RaTG13-Cov SADAGSFLARKUCG-VSARKLPPCGTCT FTDVVYRAFD12NDEVAGEARFLATKUCCHCE 57 57 MERS-CoV ELDOGGHLDSYFVVRHTMENVELEKKCVDLERCDAVAPHDFFFFURVVTFFLARKD 119 119 SARS-CoV-1 EKDEGKLLDSYFVVRHTMENVELEKKCVDLERCDAVAPHDFFFFURVUTFFLARKD 117 KT04103 Pangolin-CoV EKDEGKLLDSYFVVRHTMENVELEKKCVDLERCDAVAPHDFFFFRUKUDEVPFLSD 117 SARS-CoV-2 EKDEDKLLDSYFVVRHTMENVELEKKCVDLERCDAVAPHDFFFFRUKUDEVPFLSD 117 SARS-CoV-2 EKDEDKLLDSYFVVRHTMENVGHETINLKCCPAVARHDFFFFFLEXCOVFFLSD 117 SARS-CoV-2 EKDEDKLLDSYFVVRHTMENVGHETINLKCCPAVARHDFFFFFLEXCOVFFLSD 117 SARS-CoV-2 EKDEDKLLDSYFVVRHTFSNQHEETINLLKCCPAVARHDFFFFFLEXCOVFFLSD 117 SARS-CoV-2 EKDEDKLLDSYFVVRHTFSNQHEETINLLKCCPAVARHDFFFFFLEXCOVFFLSD 117 SARS-CoV-1 TETETMEDVTALRHTDGNCOLLKELLVTNCCDDDFFNKKDTDFVENFPLLKVAN 177 SARS-CoV-2 RITKYTMALVYARHDEGCNCTLKELLVTNCCDDFFNKKDTDFVENFPLLKVAN 177 SARS-CoV-2 RITKYTMALVYARHDEGCNCTLKELLVTNCCDDFFNKKDTDFVENFPLLKVAN 177 SARS-CoV-1 LGERVRGALLKTVQFCDAMRACTVKCTTKELLVTNCCDDFFNKKDTDFVENFPLLKVAN 177 SARS-COV-2 RITKYTMALVYARHDFFFFELCOVKNDTDFVENFPLLKVAN 177 SARS-COV-1 LGERVRGALKTVQFCDAMRACTVKCTTKCDDDFNKKDWTDFVENFPLKKVAN 177			
MERS-CoV ELDDQGHHLDSYFVVKRHTMENYELEKHCYDLLRDCDAVAPHDFFIFUR VKTPHING 119 SARS-CoV-1 EKDEEQALLDSYFVVKRHTMENYELEKHCYDLLRDCDAVAPHDFFIFUN KKTPHING 119 Fangolin-CoV EKDEEQALLDSYFVVKRHTMENYQHEETINUKUCCPAVAVHDFFFRAVGENYPHISS 117 SARS-CoV-1 EKDEEQALDSYFVVKRHTMENYQHEETINUKUCCPAVAVHDFFFRAVGENYPHISS 117 SARS-CoV-2 EKDEEDANLDSYFVVKRHTPSNYQHEETINULKOCPAVAVHDFFFRAVGENYPHISS 117 SARS-CoV-2 EKDEEDANLDSYFVVKRHTPSNYQHEETINULKOCPAVAKHDFFKRT IGONYPHISS 117 Bat_RaTGI3-CoV EKDEEDANLDSYFVVKRHTPSNYQHEETINULKOCPAVAKHDFFKRT IGONYPHISS 117 MERS-CoV EKDEEDANLDSYFVVKRHTPSNYQHEETINULKOCPAVAKHDFFKRT IGONYPHISS 117 SARS-CoV-1 EKDEEDANLDSYFVKRHTPSNYQHEETINULKOCPAVAKHDFFKRT IGONYPHISS 117 SARS-CoV-1 EKDEEDANLDSYFVKRHTPSNYQHEETINULKOCPAVAKHDFFKRT IGONYPHISS 117 SARS-CoV-1 EKDEENDLVIA LRHFEGNCOTLKEILVTYNCCDDDYNKKDWYPFKNDILKVAN 177 SARS-CoV-1 EITYTMADUVA LRHFEGNCOTLKEILVTYNCCDDPYNKKDWYPFKNDILKVAN 177 Bat_RATGI3-CoV EITYTMADUVA LRHFEGNCOTLKEILVTYNCCDDDYNKKDWYPFKNDILKVAN 177 Bat_RATGI3-COV EGRVRGLLKTVQFCDAMRACIGVUVLTUNQDLONGW PGGDFVTRKDWYPFKNDILKVAN 237 MERS-CoV-1 EGRWRGLLKTVQFCCDAMRACIGVUVLTUNQDLNGW PGGDFVTRKDWYPFKNDKYPFKNDKY			
MERS-CoV ELDQGHHL SYFVKRET MENYELEKKCYDLRDCDAVAPHDFFFFW, KUTTP LYN D 119 SARS-CoV-1 EKDEGENLL DY FVW RATHSNYQHEETIYNL/KDCAVAVHDFFFRVIGDIVYELS 117 Civet-CoV EKDEGENLL DY FVW RATHSNYQHEETIYNL/KDCAVAVHDFFFRVIGDIVYELS 117 SARS-CoV-2 EKDEDENLL DY FVW RATHSNYQHEETIYNL/KDCAVAVHDFFFRVIGDIVYELSS 117 SARS-CoV-2 EKDEDENL DY FVW RATHSNYQHEETIYNL/KDCAVAVHDFFFRVIGDIVYELSS 117 RASS-CoV-2 EKDEDENL DY FVW RATHSNYQHEETIYNL/KDCAVAXHDFFFKRVIGDIVYELSS 117 SARS-CoV-2 EKDEDENL DY FVW RATHSNYQHEETIYNL/KDCAVAXHDFFKRVIGDIVYELSS 117 RESS-CoV EKDEDENL DY FVW RATHSNYQHEETIYNL/KDCAVAXHDFFKRT I GOLVFELSS 117 SARS-CoV-1 HITYTMADLVA LAHFE GONCTKELLVTYNCCDDYFNKKDEYDFVENDILKVAN 177 SARS-CoV-1 HITYTMADLVA LAHFE GONCTKELLVTYNCCDDDYFNKKDEYDFVENDILKVAN 177 SARS-CoV-1 HITYTMADLVA LAHFE GONCTKELLVTYNCCDDDYFNKKDEYDFVENDILKVAN 177 SARS-CoV-2 HITYTMADLVA LAHFE ECNCDTLKELLVTYNCCDDDYFNKKDEYDFVENDILKVAN 177 SARS-CoV-1 LGERVRG LLKTVQCCDAMRABGTVGVLTNOCDDDYFNKKDEYDFVENDILKVAN 177 SARS-CoV-1 LGERVRG LLKTVQCCDAMRABGTVGVLTNOCDDDYFNKKDEYDFVENDILKVAN 177 SARS-CoV-1 LGERVRG LLKTVQCCDAMRABGTVGVLTLDNQDLINGV YDFGGPLYDVDSY <tr< td=""><td>Bat_Raig13-Cov</td><td></td><td>57</td></tr<>	Bat_Raig13-Cov		57
SARB-CoV-1 EKDEGNILDSYFVVRRTMSNYQHETIYNLKHCPAVAWHDFFKRVGDRVPHSD 117 Givet-CoV EKDEGNILDSYFVVRRTMSNYQHETIYNLKHCPAVAWHDFFKRVGDRVPHSD 117 SARB-CoV-2 EKDEDDNILDSYFVVRRTSNYQHETIYNLKHCPAVAKHDFFKRTGDRVPHSD 117 SARB-CoV-2 EKDEDDNILDSYFVVRRTSNYQHETIYNLKHCPAVAKHDFFKRTGDRVPHSD 117 SARB-CoV-2 EKDEDDNILDSYFVVRRTSNYQHETIYNLKHCPAVAKHDFFKRTGDRVPHSD 117 SARB-CoV EKDEDDNILDSYFVVRRTSNYQHETIYNLKHCPAVAKHDFFKRTGDRVPHSD 117 SARB-CoV EXDEDDNILDSYFVVRRTSNYQHETIYNLKHCPAVAKHDFFKRTGDRVPHSD 117 SARB-CoV EXDEDDNILDSYFVVRRTSNYQHETIYNLKHCPAVAKHDFFKRTGDRVPHSD 117 SARB-COV EXTEYTMALVY A.RHFTGENCDTKEILVTYNCCDDYFNKKDVDVENPFILKVAN 117 SARB-COV-1 EXTEYTMALVY A.RHFTGENCDTKEILVTYNCCDDYFNKKDVDVENPFILKVAN 117 SARB-COV-2 RITKYTMALVY A.RHFTGENCDTKEILVTYNCCDDYFNKKDVDVENPFILKVAN 117 SARB-COV-2 RITKYTMALVYALARHFTGENCDTKEILVTYNCCDDYFNKKDVDVENPFILKVAN 117 SARB-COV-2 RITKYTMALVYALARHFTGENCOTKEILVTYNCCDDYFNKKDVDVENPFILKVAN 117 SARB-COV-1 LGERVRALLKTVQCDAMRDAGIVGVITLDNQDLNGWV PFORDUCVLVA 117 SARB-COV-2 RITKYTMALVYALRHFTGENCOTKEILVTYNCCDDYFNKKDVDVEPVENPILKVAN 177 SARB-COV-1 LG		•••••••••••••••••••••••••••••••••••••••	
SARB-CoV-1 EKDEGNILDSYFVVRRTMSNYQHETIYNLKHCPAVAWHDFFKRVGDRVPHSD 117 Givet-CoV EKDEGNILDSYFVVRRTMSNYQHETIYNLKHCPAVAWHDFFKRVGDRVPHSD 117 SARB-CoV-2 EKDEDDNILDSYFVVRRTSNYQHETIYNLKHCPAVAKHDFFKRTGDRVPHSD 117 SARB-CoV-2 EKDEDDNILDSYFVVRRTSNYQHETIYNLKHCPAVAKHDFFKRTGDRVPHSD 117 SARB-CoV-2 EKDEDDNILDSYFVVRRTSNYQHETIYNLKHCPAVAKHDFFKRTGDRVPHSD 117 SARB-CoV EKDEDDNILDSYFVVRRTSNYQHETIYNLKHCPAVAKHDFFKRTGDRVPHSD 117 SARB-CoV EXDEDDNILDSYFVVRRTSNYQHETIYNLKHCPAVAKHDFFKRTGDRVPHSD 117 SARB-CoV EXDEDDNILDSYFVVRRTSNYQHETIYNLKHCPAVAKHDFFKRTGDRVPHSD 117 SARB-COV EXTEYTMALVY A.RHFTGENCDTKEILVTYNCCDDYFNKKDVDVENPFILKVAN 117 SARB-COV-1 EXTEYTMALVY A.RHFTGENCDTKEILVTYNCCDDYFNKKDVDVENPFILKVAN 117 SARB-COV-2 RITKYTMALVY A.RHFTGENCDTKEILVTYNCCDDYFNKKDVDVENPFILKVAN 117 SARB-COV-2 RITKYTMALVYALARHFTGENCDTKEILVTYNCCDDYFNKKDVDVENPFILKVAN 117 SARB-COV-2 RITKYTMALVYALARHFTGENCOTKEILVTYNCCDDYFNKKDVDVENPFILKVAN 117 SARB-COV-1 LGERVRALLKTVQCDAMRDAGIVGVITLDNQDLNGWV PFORDUCVLVA 117 SARB-COV-2 RITKYTMALVYALRHFTGENCOTKEILVTYNCCDDYFNKKDVDVEPVENPILKVAN 177 SARB-COV-1 LG	MERS-COV	ELDDOGHHLDSYFVVKRHTMENYELEKHCYDLLRDCDAVAPHDFFTFDVDKVKTPHTVRD	119
Civet-CoV EKDEGNILDSYFVWRRHT/SNYQHEETIYNLLKDCPAVAKHDFFRRVGORVPHSSD 117 Pangolin-CoV EKDEGNILDSYFVWRRT/SNYQHEETIYNLLKDCPAVAKHDFFRRVGORVPHSSD 117 SAR8-CoV-2 EKDEDDNILDSYFVWRRT/SNYQHEETIYNLLKDCPAVAKHDFFRRVGORVPHSSD 117 RthEDDNILDSYFVWRRT/SNYQHEETIYNLLKDCPAVAKHDFFRRVGORVPHSSD 117 RthEDDNILDSYFVWRRT/SNYQHEETIYNLLKDCPAVAKHDFFRRVGORVPHSSD 117 RthEDDNLDSYFVWRRT/SNYQHEETIYNLLKDCPAVAKHDFFRRVGORVPHSSD 117 RthEDDNLDSYFVWRRT/SNYQHEETIYNLLKDCPAVAKHDFFRRVGORVPHSSD 117 * *:; **::*:*****:::*::*:*:******:::******:::****	SARS-CoV-1		117 K73&103
Pangolin-CoVEKDEGGNLT SYTUKRHTFSNYGHEETIYNLLKDCPAVAKHDFFKRITGDWVPTSD117SARS-CoV-2EKDEDDNLDSYFVV RHTFSNYGHEETIYNLLKDCPAVAKHDFFKRITGDWVPTSD117Bat_RaTG13-CoVEKDEDDNLDSYFVV RHTFSNYGHEETIYNLLKDCPAVAKHDFFKRITGDWVPTSD117Bat_RATG13-CoVRITEYTMEDUVARHTFSNYGHEETIYNLLKDCPAVAKHDFFKRITGDWVPTSD117MERS-CoVRITEYTMEDUVARHTSNYGHEETIYNLLKDCPAVAKHDFFKRITGDWVPTSD117SARS-CoV-1RITEYTMEDUVARHTSNYGHEETIYNLLKDCPAVAKHDFFKRITGDWVPTSD117Civet-CoVRITEYTMADUVARHTEGNCOTLKEILVTYNCCDDYYNKKDWDVDWAPDILKVKN177SARS-CoV-2RITEYTMADUVARHTEGNCOTLKEILVTYNCCDDYYNKKDWDPVENPDILKVKN177SARS-CoV-2RITEYTMADUVARHTEGNCOTLKEILVTYNCCDDYYNKKDWDPVENPDILKVKN177SARS-CoV-2RITEYTMADUVALRHFEGCNCOTLKEILVTYNCCDDYYNKKDWDPVENPDILKVKN177SARS-CoV-2RITEYTMADUVALRHFEGCNCOTLKEILVTYNCCDDYYNKKDWDPVENPDILKVKN177SARS-CoV-2RITEYTMADUVALRHFEGCNCOTLKEILVTYNCCDDYYNKKDWDPVENPDILKVKN177SARS-CoV-1LGERVRGALLKTVQFCDAMRAAGUVUTLDNDDINGKWPFGDFUTTPGSGVEVVDSY237YMAHan_Std-CoVLGERVRGALLKTVQFCDAMRAAGUVUTLDNDDINGKWPFGDFUTTPGSGVEVVDSY237SARS-CoV-2LGERVRGALLKTVQFCDAMRAAGUVUTLDNDDINGKWPFGDFUTTPGSGVEVVDSY237SARS-CoV-2LGERVRGALLKTVQFCDAMRAAGUVUTLDNDDINGWPFGERTUTTRGSGVEVVDSY237SARS-CoV-2LGERVRGALLKTVQFCDAMRAAGUVUTLDNDDINGWPFGERTUTTRGSGVEVVDSY237SARS-CoV-1LGERVRGALLKTVQFCDAMRAAGUVUTLDNDDINGWPFGERTUTTRGSGVEVVDSY237SARS-CoV-2YSLLMPLITTRALASSH MTD_KTYFYIKMULKYDFTERLLENPYFYWDQTYFN297SARS-CoV-1YSLLMPLITTRALASSH MTD_KT			
Wuhan_Std-CoVEKDEDDNLIDSYFVVKRHTSNYQHEETIYNLLKDCPAVAKHDFFKFRIGONYPETSKO117Bat_RaTG13-CoVEKDEDDNLIDSYFVVKRHTSNYQHEETIYNLLKDCPAVAKHDFFKFRIGONYPETSKO117MERS-CoVRITEYTYMDUVTALRHFTQN-SEVLKAILVKYGCCDVTYFENKLUFDFVENSULKY117SARS-CoV-1RITEYTMADUVTALRHFTQN-SEVLKAILVKYGCCDVTYFENKLUFDFVENSULKY177Pangolin-CoVRITEYTMADUVTALRHFTQN-SEVLKAILVKYGCCDUTYFENKLUFDFVENSULKY177SARS-CoV-2RITEYTMADUVTALRHFTGENCDTLKEILVTYNCCDDYFNKRDYDFVENSULKY177SARS-CoV-2RITEYTMADUVTALRHFTGENCDTLKEILVTYNCCDDYFNKRDYDFVENSULKY177SARS-CoV-2RITEYTMADUVTALRHFTGENCDTLKEILVTYNCCDDYFNKRDYDFVENSULKY177SARS-CoV-1RITEYTMADUVTALRHFTGENCDTLKEILVTYNCCDDYFNKDYDYPENSULKY177SARS-CoV-1LGERVRGALKTVOFCDAMRDAGIVGVLTLDNDDINGWYPEDDTURVEND177Civet-CoVLGERVRGALKTVOFCDAMRDAGIVGVLTLDNDDNGWYPEDDTURVEND237SARS-CoV-1LGERVRGALKTVOFCDAMRDAGIVGVLTLDNDDNGWYPEDDTUVAPGCGVLTUDSY237SARS-CoV-2LGERVRGALLKTVOFCDAMRDAGIVGVLTLDNDDNGWYPEDDTUTFGSGVVVDSY237Bat_RaTG13-CoVLGERVRGALLKTVOFCDAMRDAGIVGVLTLDNDDNGWYPEDDTUTFGSGVVUDSY237SARS-COV-2LGERVRGALLKTVOFCDAMRDAGIVGVLTLDNDDNGWYPEDDTUFFKYWDDTYFN297SARS-COV-2LGERVRGALLKTVOFCDAMRDAGIVGVLTLDNDDNGWYPEDDTUFFKYWDDTYFN297SARS-COV-1LGERVRGALLKTVOFCDAMRDAGIVGVLTLDNDDNGWYPEDDTUFFKYWDDTYFN297SARS-COV-1SILMPTITUTTALAASSHYPTDTAKYLKYDETSERLLFDRYFKWDDTYFN297SARS-COV-1YSILMPTITUTTALAASSHYPTDTAKYLKYDTSERLLFDRYFKWDDTYFN297SARS-COV-1YSILMPT			
Bat_RaTG13-CovEKDEDDNLISYFVYKRHT SNYQHEETIYHLKDCPAAKHDFFKFRI KORVPETSKO117MERS-CoVRITEYTMYDLYTALRHFTON-SEVLKAILVKYGCCDVTYENKLDIVDFVENDILKVKN178SARS-CoV-1RITEYTMADLYTALRHFTON-SEVLKAILVKYGCCDVTYENKLDIVDFVENDILKVKN177Pangolin-CoVRITEYTMADLYTALRHFTEGNCOTLKEILVTYNCCDDYFNKKDUYDFVENDILKVKN177Pangolin-CoVRITEYTMADLYTALRHFTEGNCOTLKEILVTYNCCDDYFNKKDUYDFVENDILKVKN177Pangolin-CoVRITEYTMADLYTALRHFTEGNCOTLKEILVTYNCCDDYFNKKDUYDFVENDILKVKN177Naka-Std-CoVRITEYTMADLYTALRHFTEGNCOTLKEILVTYNCCDDYFNKKDUYDFVENDILKVKN177MERS-CoVRITEYTMADLYTALRHFTEGNCOTLKEILVTYNCCDDYFNKKDUYDFVENDILKVKN177MERS-CoVLGERVRCALLKTVQFCDAMRDAGIVGVLTLDNODLNGKWYDFGDFUVTQFGSGVFUNDSY238SARS-COV-1LGERVRCALLKTVQFCDAMRDAGIVGVLTLDNODLNGKWYDFGDFUVTGSGSVFUNDSY237SARS-COV-2LGERVRCALLKTVQFCDAMRDAGIVGVLTLDNODLNGKWYDFGDFUTTFGSGVFUNDSY237SARS-COV-2LGERVRCALLKTVQFCDAMRDAGIVGVLTLDNODLNGWYDFGDFUTTFGSGVFUNDSY237SARS-COV-2LGERVRCALLKTVQFCDAMRDAGIVGVLTLDNODLNGWYDFGDFUTTFGSGVFUNDSY237SARS-COV-2LGERVRCALLKTVQFCDAMRDAGIVGVLTLDNODLNGWYDFGDFUTTFGSGVFUNDSY237SARS-COV-2LGERVRCALLKTVQFCDAMRDAGIVGVLTLDNODLNGWYDFGDFUTTFGSGVFUNDSY237SARS-COV-2LGERVRCALLKTVQFCDAMRDAGIVGVLTLDNODLNGWYDFGDFUTTFGSGVFUNDSY237SARS-COV-2LGERVRCALLKTVQFCDAMRDAGIVGVLTLDNODLNGWYDFGDFUTTFGSGVFUNDSY237SARS-COV-2VSTLMPTLTUTTALTARASHVARFLIKKDLYDFTSELLLPDYFKWDDTYFN297SARS-COV-2VSTLMPTLTUTTALTARASHVARFLIKKDLYDFTSELLLPDYFKWDDTYFN2	SARS-CoV-2	EKDEDDNLIDSYFVVKRHTFSNYQHEETIYNLLKDCPAVAKHDFFKFRIDGDMVPHISRQ	117 R116
	Wuhan Std-CoV	EKDEDDNLIDSYFVVKRHTFSNYQHEETIYNLLKDCPAVAKHDFFKFRIDGDWVPHISRD	117
MERS-COV RJ TEYTMADLVTALRHFT ON-SEVIKA ILVKYGCCDUTYFENKLWFDFVENPSVIGVCT 178 MERS-COV-1 RJ TKYTMADLVTALRHFT BENCDTLKE ILVTYNCCDDDYFNKKDWJDFVENPSVILKVYAN 177 Pangolin-CoV RJ TKYTMADLVTALRHFT BENCDTLKE ILVTYNCCDDDYFNKKDWJDFVENPSILKVYAN 177 SARS-COV-2 RJ TKYTMADLVTALRHFT BENCDTLKE ILVTYNCCDDDYFNKKDWJDFVENPSILKVYAN 177 Wuhan_Std-CoV RJ TKYTMADLVYALRHFT BENCDTLKE ILVTYNCCDDDYFNKKDWJDFVENPSILKVYAN 177 Bat_RATG13-CoV RJ TKYTMADLVYALRHFT BENCDTLKE ILVTYNCCDDDYFNKKDWJDFVENPSILKVYAN 177 MERS-COV RJ TKYTMADLVYALRHFT BENCDTLKE ILVTYNCCDDDYFNKKDWJDFVENPSILKVYAN 177 MERS-COV RJ TKYTMADLVYALRHFT BENCDTLKE ILVTYNCCDDDYFNKKDWJDFVENPSILKVYAN 177 MERS-COV LGERVRG ALLNTVKFCDHMVKGUGUGULTLDNQLNGKY DFCDP VTAPEGGVFUDSY 237 SARS-COV-1 LGERVRG ALLKTVQFCDANRAGIVGVLTLDNQDLNGKY DFCDP VTAPEGGVFUDSY 237 SARS-COV-2 LGERVRG ALLKTVQFCDANRAGIVGVLTLDNQDLNGKY DFCDF I OTTFOSGVFVUDSY 237 SARS-COV-2 LGERVRG ALLKTVQFCDANRAGIVGVLTLDNQDLNGKY DFCDF I OTTFOSGVFVUDSY 237 SARS-COV-1 LGERVRG ALLKTVQFCDANRAGIVGVLTLDNQDLNGKY DFCDF I OTTFOSGVFVUDSY 237 SARS-COV-2 LGERVRG ALLKTVQFCDANRAGIVGVLTLDNQDLNGWY DFCDF I OTTFOSGVFVUDSY 237 SARS-COV-1 <t< td=""><td>Bat_RaTG13-CoV</td><td>EKDEDDNLIDSYFVVKRHTFSNYQHEETIYNLLKDCPAVAKHDFFKFRIDGDMVPHISRQ</td><td>117</td></t<>	Bat_RaTG13-CoV	EKDEDDNLIDSYFVVKRHTFSNYQHEETIYNLLKDCPAVAKHDFFKFRIDGDMVPHISRQ	117
SARS-COV-1RITKYTMA LV A LRHF EGNCDTLKE ILVTYNCCDDDYFNKKDYDFVENPDILRV(AN EITKYTMADLVALRHF EGNCDTLKE ILVTYNCCDDYFNKKDWDFVENPDILRV(AN 177177 177SARS-COV-2RITKYTMADLVALRHFDEGNCDTLKEILVTYNCCDDYFNKKDWDFVENPDILRV(AN INTADLVALRHFDEGNCDTLKEILVTYNCCDDYFNKKDWDFVENPDILRV(AN 177177SARS-COV-2RITKYTMADLVALRHFDEGNCDTLKEILVTYNCCDDYFNKKDWDFVENPDILRV(AN INTADLVALRHFDEGNCDTLKEILVTYNCCDDYFNKKDWDFVENPDILRV(AN INTAL 		* *::.: : <mark>****:****</mark> :.**: *: *:*:** *** *** * :*	
SARS-COV-1RITKYTMA LV A LRHF EGNCDTLKE ILVTYNCCDDDYFNKKDYDFVENPDILRV(AN EITKYTMADLVALRHF EGNCDTLKE ILVTYNCCDDYFNKKDWDFVENPDILRV(AN 177177 177SARS-COV-2RITKYTMADLVALRHFDEGNCDTLKEILVTYNCCDDYFNKKDWDFVENPDILRV(AN INTADLVALRHFDEGNCDTLKEILVTYNCCDDYFNKKDWDFVENPDILRV(AN 177177SARS-COV-2RITKYTMADLVALRHFDEGNCDTLKEILVTYNCCDDYFNKKDWDFVENPDILRV(AN INTADLVALRHFDEGNCDTLKEILVTYNCCDDYFNKKDWDFVENPDILRV(AN INTAL 			
Civet-CoV Pangolin-COV Pangolin-COV Pango			
Pangolin-CoVRITKYTMADLV ALRHET EGNCDTLKE ILVTYNCCDDEYENKKD VDEFVENPDILRV (AN ALRHET EGNCDTLKE ILVTYNCCDDEYENKKD VDEFVENPDILRV (AN ALRHET EGNCDTLKE ILVTYNCCDDDYENKKD VDEFVENPDILRV (AN Bat_RATG13-CoV177 RITKYTMADLV ALRHET EGNCDTLKE ILVTYNCCDDDYENKKD VDEFVENPDILRV (AN ALRHET EGNCDTLKE ILVTYNCCDDDYENKKD VDEFVENPDILRV (AN ALRHET EGNCDTLKE ILVTYNCCDDDYENKKD VDEFVENPDILRV (AN ALRHET EGNCDTLKE ILVTYNCCDDDYENKKD VDEFVENPDILRV (AN ALRHET EGNCDTLRE ILVTYNCCDDATEN AND ALRHET EGNC (AND ALRHET EGNE AND ALRHET EGNE A			- · ·
SARS-CoV-2RITKYTMA LUYALRHFDEGNCDTLKEILVTYNCCDDDYFNKKDWYDFVENPDILRVYAN177D126Wuhan_Std-CoVRITKYTMADLVYALRHFDEGNCDTLKEILVTYNCCDDDYFNKKDWYDFVENPDILRVYAN177Bat_RaTG13-CoVRITKYTMADLVYALRHFDEGNCDTLKEILVTYNCCDDDYFNKKDWYDFVENPDILRVYAN177MERS-COVRITKYTMADLVYALRHFDEGNCDTLKEILVTYNCCDDDYFNKKDWYDFVENPDILRVYAN177MERS-COVLGERVRQAILNTVKFCDHWYKGLVGVLTLDNQDLNGKWY DFGDFVVAPGCCVFIVDSY238SARS-CoV-1LGERVRQSLLKTVQFCDAMRDAGIVGVLTLDNQDLNGKWY DFGDFVVAPGCCVFIVDSY237Pangolin-CoVLGERVRQALLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY DFGDFUTFFGSCVFVVDSY237SARS-CoV-2LGERVRQALLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY DFGDFUTFFGSCVFVVDSY237Wuhan_Std-CoVLGERVRQALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY DFGDFUTFFGSCVFVVDSY237Bat_RATG13-CoVLGERVRQALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY DFGDFUTFFGSCVFVVDSY237SARS-CoV-1VSYLMPVLSWTDCLAAETRR COTNKPLIEWPLTEVTYKVQLFEKYFKYWQTY PN298SARS-COV-1YSILMPILTITRALAAESHWARLAKPLKWDLLKYDFT ERLCLFDRYFKYWQTY PN297Pangolin-CoVYSILMPILTITRALAAESHWARLAKPIKWDLLKYDFT ERLLFPRYFKYWQTY PN297SARS-COV-2YSILMPILTITRALAAESHVDTDTKPYIKWDLLKYDTFT ERLLFPRYFKYWQTY PN297SARS-COV-2YSILMPILTITRALAAESHVDTDTKPYIKWDLLKYDTFT ERLLFPRYFKYWQTY PN297SARS-COV-2YSILMPILTITRALAESHVDTDTKPYIKWDLLKYDTFT ERLLFPRYFKYWQTY PN297SARS-COV-1VSILMPILTITRALAESHVDTDTKPYIKWDLLKYDTFT ERLLFPRYFKYWQTY PN297SARS-COV-1VSILMPILTITRALAESHVDTDTKPYIKWDLLKYDTFT ERLLFPRYFKYWQTY PN297SARS-COV-1CINCLDDRCILHCANFNVLFTVFPTSFGPLVRKIFVDGVPFVVSTCYHFRE			
Wuhan_Std-CoV Bat_RaTG13-CoVRITKYTMADLV ALRHFIEGNCDTLKEILVTYNCCDDDYFNKKDWYDFVENPDLRV AN RITKYTMADLV ALRHFIEGNCDTLREILVTYNCCDDDYFNKKDWYDFVENPDLRV AN RITKYTMADLV ALRHFIEGNCDTLREILVTYNCCDDDYFNKKDWYDFVENPDLRV AN RITKYTMADLV ALRHFIEGNCDTLREILVTYNCCDDDYFNKKDWYDFVENPDLRV AN N************************************			
Bat_RTG13-CoVRITKYTMADLVTALRHFTEGNCDTLREILVTYNCCDDDYFNKKDWYDFVENFDILRVKAN ************************************			
MERS-CoVLGERVRQ AILNTVKFCDHMVKAGLVGVLTLDNQDLNGKVY PFGDFVLTQPGSGVAIVDSY238SARS-CoV-1LGERVRQ SLLKTVQFCDAMRDAGIVGVLTLDNQDLNGKVY PFGDFVQVAPGCGVFIVDSY237Civet-CoVLGERVRQ SLLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY PFGDFVQVAPGCGVFIVDSY237Pangolin-CoVLGERVRQ ALLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY PFGDFIVTFFGSGVFVVDSY237SARS-CoV-2LGERVRQ ALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY PFGDFIVTFFGSGVFVVDSY237Bat_RaTG13-CoVLGERVRQ ALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY PFGDFIVTFFGSGVFVVDSY237Bat_RaTG13-CoVLGERVRQ ALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY PFGDFI TTFFGSGVFVVDSY237Bat_RaTG13-CoVLGERVRQ ALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY PFGDFI TTFFGSGVFVVDSY237Civet-CoVLGERVRQ ALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY PFGDFI TTFFGSGVFVVDSY237Bat_RaTG13-CoVLGERVRQ ALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY PFGDFI TTFFGSGVFVVDSY237YY************************************	_		
MERS-CoVLGERVRCAILNTVKFCDHMVKAGUVGVLTLDNQDLNGKWYPGDTVTQFGSGVAUDSY238SARS-CoV-1LGERVRCSLLKTVQFCDAMRDAGUVGVLTLDNQDLNGKWYPGDTVTQFGGCGVFUVDSY237Civet-CoVLGERVRCALLKTVQFCDAMRDAGUVGVLTLDNQDLNGWYPGDTIDTTFGSGVFVVDSY237Pangolin-CoVLGERVRCALLKTVQFCDAMRNAGUVGVLTLDNQDLNGWYPGDTIDTTFGSGVFVVDSY237SARS-CoV-2LGERVRCALLKTVQFCDAMRNAGUVGVLTLDNQDLNGWYPGDTIDTTFGSGVFVVDSY237Bat_RaTG13-CoVLGERVRCALLKTVQFCDAMRNAGUVGVLTLDNQDLNGWYPGDTIDTTFGSGVFVVDSY237Bat_RaTG13-CoVLGERVRCALLKTVQFCDAMRNAGUVGVLTLDNQDLNGWYPGDTIDTTFGSGVFVVDSY237SARS-CoV-2LGERVRCALLKTVQFCDAMRNAGUVGVLTLDNQDLNGWYPGDTIDTTFGSGVFVDSY237SARS-CoVYSYLMPVLSMTDCAAETHR CDFNKPLIEWPLTEYDFTIYKVQLFEKYFKYWDQTYFAN298SARS-CoV-1YSILMPILFILTRALAAESHMUNDLAKPLIKWDLLKYDFT ERLCLFDRYFKYWDQTYFN297Civet-CoVYSILMPILFILTRALTAESHVDTDTKPYIKWDLKYDFT ERLCLFDRYFKYWDQTYFN297Pangolin-CoVYSILMPILFILTRALTAESHVDTDTKPYIKWDLKYDFT ERLKLFDRYFKYWDQTYFN297SARS-CoV-2YSILMPILFILTRALTAESHVDTDTKPYIKWDLKYDFT ERLKLFDRYFKYWDQTYFN297Bat_RaTG13-CoVYSILMPILFILTRALTAESHVDTDTKPYIKWDLKYDFT ERLKLFDRYFKYWDQTYFN297Wuhan_Std-CoVYSILMPILFILTRALTAESHVDTDTKPYIKWDLKYDFT ERLKLFDRYFKYWDQTYFN297SARS-CoV-2YSILMPILFILTRALTAESHVDTDTKPYIKWDLKYDFT ERLKLFDRYFKYWDQTYFN297SARS-CoVCVNCIDDRCULHCANFNVLFSTVFPTSFGPLVRKIFVDGVPFVSTGYHFRELGVVNQ357GincLDDRCILHCANFNVLFSTVFPTSFGPLVRKIFVDGVPFVSTGYHFRELGVVNQ357SARS-CoVCVNCLDDRCILHCANFNVLFSTVFPTSFGPLVRKIFVDGVPFVSTGYHFRELGVVNQ357 <td< td=""><td>Bat_Raigis-COV</td><td></td><td>1//</td></td<>	Bat_Raigis-COV		1//
SARS-CoV-1LGERVRG SLLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY DFGDF VOVAPGCGVFIVDSY237Civet-CoVLGERVRG SLLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY DFGDF VOVAPGCGVFIVDSY237Pangolin-CoVLGERVRG ALLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY DFGDF IDTTPGSGVFVVDSY237SARS-CoV-2LGERVRG ALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY DFGDF IDTTPGSGVFVVDSY237Wuhan_Std-CoVLGERVRG ALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY DFGDF IDTTPGSGVFVVDSY237Bat_RaTG13-CoVLGERVRG ALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY DFGDF IDTTPGSGVFVDSY237MERS-CoVYSYLMPVLS MTDC AAETHR CCD FNKPLIEWPLT SYDFT YKVQ LFEKYFKYWDQTYFAN298SARS-CoV-1YSILMPILT LTRALAAESHMAAD AKPLIKWDLLKYDFTF ERLGLFDRYFKYWDQTYFPN297Civet-CoVYSILMPILT LTRALAAESHMAAD AKPLIKWDLLKYDFTF ERLGLFDRYFKYWDQTYFPN297SARS-CoV-2YSILMPILT LTRALAAESHMAAD AKPLIKWDLLKYDFTF ERLKLFDRYFKYWDQTYFPN297SARS-CoV-2YSILMPILT LTRALFAESHV DTD TKPYIKWDLLKYDFTF ERLKLFDRYFKYWDQTYFPN297SARS-CoV-2YSILMPILT LTRALFAESHV DTD TKPYIKWDLLKYDFTF ERLKLFDRYFKYWDQTYFPN297SARS-CoV-2YSILMPILT LTRALFAESHV DTD TKPYIKWDLLKYDFTF ERLKLFDRYFKYWDQTYFPN297SARS-CoV-1CUNCTDDRCVHCANFNVLFS TVFPPTSFGPIVRKIFVDGVPFV SCFYHYKUDQTYFPN297Wuhan_Std-CoVYSILMPILT LTRALFAESHV DTD TKPYIKWDLLKYDFTF ERLKLFDRYFKYWDQTYFPN297SARS-CoV-1CUNCTDDRCVHCANFNVLFS TVFPPTSFGPIVRKIFVDGVPFV SCFYHFRELGVVHNQ357Civet-CoVCUNCTDDRCVHCANFNVLFS TVFPPTSFGPIVRKIFVDGVPFV SCFYHFRELGVVHNQ357SARS-CoV-1CUNCLDDRCILHCANFNVLFS TVFPPTSFGPLVRKIFVDGVPFV STGYHFRELGVVHNQ357SARS-COV-2CVNCLDD			
SARS-CoV-1LGERVRG SLLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY DFGDF VOVAPGCGVFIVDSY237Civet-CoVLGERVRG SLLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY DFGDF VOVAPGCGVFIVDSY237Pangolin-CoVLGERVRG ALLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY DFGDF IDTTPGSGVFVVDSY237SARS-CoV-2LGERVRG ALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY DFGDF IDTTPGSGVFVVDSY237Wuhan_Std-CoVLGERVRG ALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY DFGDF IDTTPGSGVFVVDSY237Bat_RaTG13-CoVLGERVRG ALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY DFGDF IDTTPGSGVFVDSY237MERS-CoVYSYLMPVLS MTDC AAETHR CCD FNKPLIEWPLT SYDFT YKVQ LFEKYFKYWDQTYFAN298SARS-CoV-1YSILMPILT LTRALAAESHMAAD AKPLIKWDLLKYDFTF ERLGLFDRYFKYWDQTYFPN297Civet-CoVYSILMPILT LTRALAAESHMAAD AKPLIKWDLLKYDFTF ERLGLFDRYFKYWDQTYFPN297SARS-CoV-2YSILMPILT LTRALAAESHMAAD AKPLIKWDLLKYDFTF ERLKLFDRYFKYWDQTYFPN297SARS-CoV-2YSILMPILT LTRALFAESHV DTD TKPYIKWDLLKYDFTF ERLKLFDRYFKYWDQTYFPN297SARS-CoV-2YSILMPILT LTRALFAESHV DTD TKPYIKWDLLKYDFTF ERLKLFDRYFKYWDQTYFPN297SARS-CoV-2YSILMPILT LTRALFAESHV DTD TKPYIKWDLLKYDFTF ERLKLFDRYFKYWDQTYFPN297SARS-CoV-1CUNCTDDRCVHCANFNVLFS TVFPPTSFGPIVRKIFVDGVPFV SCFYHYKUDQTYFPN297Wuhan_Std-CoVYSILMPILT LTRALFAESHV DTD TKPYIKWDLLKYDFTF ERLKLFDRYFKYWDQTYFPN297SARS-CoV-1CUNCTDDRCVHCANFNVLFS TVFPPTSFGPIVRKIFVDGVPFV SCFYHFRELGVVHNQ357Civet-CoVCUNCTDDRCVHCANFNVLFS TVFPPTSFGPIVRKIFVDGVPFV SCFYHFRELGVVHNQ357SARS-CoV-1CUNCLDDRCILHCANFNVLFS TVFPPTSFGPLVRKIFVDGVPFV STGYHFRELGVVHNQ357SARS-COV-2CVNCLDD	MERS-CoV	LGERVRGAILNTVKFCDHMVKAGLVGVLTLDNODLNGKWYDFGDFVLTOPGSGVAIVDSY	238
Civet-CoVLGERVRQ SLLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY YFGDFVQVAPGCGVFIVDSY237Pangolin-CoVLGERVRQALLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY YFGDFICTTPGSGVFVVDSY237SARS-CoV-2LGERVRQALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY YFGDFICTTPGSGVPVVDSY237Wuhan_Std-CoVLGERVRQALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY YFGDFICTTPGSGVPVVDSY237Bat_RaTG13-CoVLGERVRQALLKTVQFCDAMRNAGIVGVLTLDNQDLNGWY YFGDFICTTPGSGVPVVDSY237Bat_RATG13-CoVLGERVRQALLKTVQFCDAMRDAGIVGVLTLDNQDLNGWY YFGDFICTTPGSGVPVVDSY237MERS-CoVYSYLMPVLSMTDCLAAETHR DCDFNKPLIEWPLT YDFTI YKVQLFEKYFKWDQTYFAN298SARS-CoV-1YSILMPILT LTRALAAESHN NG AKPLIKWDLLKYDFT ERLCLFDRYFKWDQTYFPN297Civet-CoVYSILMPILT LTRALAAESHV DTD TKPYIKWDLLKYDFT ERLCLFDRYFKWDQTYFPN297Pangolin-CoVYSILMPILT LTRALTAESHV DTD TKPYIKWDLLKYDFT ERLCLFDRYFKWDQTYFPN297SARS-CoV-2YSLLMPILT LTRALTAESHV DTD TKPYIKWDLLKYDFT ERLELFDRYFKWDQTYFPN297Wuhan_Std-CoVYSILMPILT LTRALTAESHV DTD TKPYIKWDLLKYDFT ERLELFDRYFKWDQTYFPN297Bat_RATG13-CoVYSILMPILT LTRALTAESHV DTD TKPYIKWDLLKYDFT ERLELFDRYFKWDQTYFPN297***********************************	SARS-CoV-1		237
SARS-CoV-2LGERVROALLKTVOFCDAMRNAGIVGVLTLDNODLNGNWYDFGDFIOTTPGSGVPVUDSY2.37Wuhan_Std-CoVLGERVRCALLKTVOFCDAMRNAGIVGVLTLDNODLNGNWYDFGDFIOTTPGSGVPVUDSY2.37Bat_RaTG13-CoVLGERVRCALLKTVOFCDAMRDAGIVGVLTLDNODLNGNWYDFGDFIOTTPGSGVPTUDSY2.37Bat_RaTG13-CoVLGERVRCALLKTVOFCDAMRDAGIVGVLTLDNODLNGNWYDFGDFIOTTPGSGVPTUDSY2.37MERS-CoVYSYLMPVLSMTDCLAAETHR DCDFNKPLIEWPLTEYDFTDYKVQLFEKYFKYWDQTYEN2.98SARS-CoV-1YSILMPILTITRALAAESHMAADLAKPLIKWDLLKYDFTEERLCLFDRYFKYWDQTYEN2.97Civet-CoVYSILMPILTITRALAAESHMAADLAKPLIKWDLLKYDFTEERLCLFDRYFKYWDQTYEN2.97Pangolin-CoVYSILMPILTITRALAAESHVDTDITKPYIKWDLLKYDFTEERLCLFDRYFKYWDQTYEN2.97Wuhan_Std-CoVYSILMPILTITRALTAESHVDTDITKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEN2.97Wuhan_Std-CoVYSILMPILTITRALTAESHVDTDITKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEN2.97Bat_RATG13-CoVYSILMPILTITRALTAESHVDTDITKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEN2.97Wuhan_Std-CoVCVNCTDDRCVLHCANFNVLFAMTMPKTCFGPIVRKIFVDGVPFVVSCCYHYKELGVVNNQ3.58SARS-CoV-1CINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSCCYHYKELGVVNQ3.57Civet-CoVCINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVNQ3.57Pangolin-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVNQ3.57SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVNQ3.57Bat_RATG13-COVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVNQ3.57Bat_RATG13-COVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVNQ3.57BATCVNCLDDRCILHCANFNV	Civet-CoV		237
Wuhan_Std-CoV Bat_RaTG13-CoVLGERVRCALLKTVQFCDAMRNAGIVGVLTLDNQDLNGNWYDFGDEIOTTFGSGVFWVDSY LGERVRCALLKTVQFCDAMRDAGIVGVLTLDNQDLNGNWYDFGDEIOTTFGSGVFWVDSY t******237MERS-CoV SARS-CoV-1 Civet-CoVYSYLMPVLSMTDCLAAETHR DCDFNKPLIEWPLTEYDFTDYKVQLFEKYFKYWDQTYEAN YSILMPILTLTRALAAESHMONDLAKPLIKWDLLKYDFTEERLCLFDRYFKYWDQTYEPN 297 SARS-CoV-2 SARS-CoV SARS-CoV298 YSILMPILTLTRALAAESHMONDLAKPLIKWDLLKYDFTEERLCLFDRYFKYWDQTYEPN 297 SARS-CoV-2 YSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN 297 SARS-CoV Bat_RATG13-CoV298 YSILMPILTLTRALTAESHVDTDLTKPYIKWDLKYDFTEERLKLFDRYFKYWDQTYEPN 297 YSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN 297 YSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN 297 SARS-CoV-2 WUhan_Std-CoV SARS-CoV-1 CINCIDDRCVLHCANFNVLFATTMEKTCFGFIVRKIFVDGVPFVSCGVHYKELGLVNNM 358 SARS-COV-1 CINCIDDRCVLHCANFNVLFATTMEKTCFGFIVRKIFVDGVPFVSCGVHYKELGLVNNM 358 SARS-COV-2 CVNCIDDRCVLHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVSTGVHFRELGVVHNQ 357 Civet-CoV Pangolin-CoVCVNCTDDRCVLHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVSTGVHFRELGVVHNQ 357 GXRS-COV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVSTGVHFRELGVVHNQ 357 SARS-COV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVSTGVHFRELGVVHNQ 357 SARS-COV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVSTGVHFRELGVVHNQ 357 SARS-COV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVSTGVHFRELGVVHNQ 357 SARS-COV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVSTGVHFRELGVVHNQ 357 SARS-COV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVSTGVHFRELGVVHNQ 357 SARS-COV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVSTGVHFRELGVVNQ 357 SARS-COV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVSTGVHFRELGVVNQ 357 SARS-COV-2 CVNCLDDRCILHCANFNVLFSTVFPTSFGPLVRKIFVDGVPFVVSTGVHFR	Pangolin-CoV	LGERVRQALLKTVQFCDAMRDAGIVGVLTLDNQDLNGNWY <mark>DFGDF</mark> IQTTPGSGVPVVDSY	237
Bat_RaTG13-CoVLGERVRCALLKTVQFCDAMRDAGIVGVLTLDNQDLNGVVYPGDFLIDTTPGSGVFTVDSY *******237MERS-CoVYSYLMPVLSMTDCLAAETHR DCDFNKPLIEWPLTYDFT1YKVQLFEKYFKYWDQTYBAN SARS-COV-1298Civet-CoVYSILMPILTLTRALAAESHMAACLAKPLIKWDLLKYDFTERLCLFDRYFKYWDQTYBPN YSILMPILTLTRALAAESHVDTDLTKPYIKWDLLKYDFTERLCLFDRYFKYWDQTYBPN 297297Pangolin-CoVYSILMPILTLTRALAAESHVDTDLTKPYIKWDLLKYDFTERLKLFDRYFKYWDQTYBPN 297297SARS-CoV-2YSILMPILTLTRALAAESHVDTDLTKPYIKWDLLKYDFTERLKLFDRYFKYWDQTYBPN 297297SARS-CoV-2YSILMPILTLTRALAESHVDTDLTKPYIKWDLLKYDFTERLKLFDRYFKYWDQTYBPN 297297Bat_RaTG13-CoVYSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTERLKLFDRYFKYWDQTYPN 297297MERS-CoVCVNCTDDRCVLHCANFNVLFAMTMPKTCFGPIVRKIFVDGVPFV SCYHYKELGUVNM 358358SARS-CoV-1CINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFV STYHFRELGVV HNQ 357357MERS-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFV STYHFRELGVV HNQ 357357MAN-Std-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFV STYHFRELGVV HNQ 357357Muhan_Std-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFV STYHFRELGVV HNQ 357357SARS-COV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFV STYHFRELGVV HNQ 357357SARS-COV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFV STYHFRELGVV HNQ 357357SARS-COV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFV STYHFRELGVV HNQ 357357SARS-COV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFV STYHFRELGVV HNQ 357357SARS-COV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFV STYHFRELGVV HNQ 3	SARS-CoV-2	LGERVRQALLKTVQFCDAMRNAGIVGVLTLDNQDLNGNWYDFGDFIQTTPGSGVPVVDSY	237 D218
MERS-CoVYSYLMPVL\$MTDCAAESHMADAAESHMADAKPLIKWDLYKVQLFEKYFKYWDQTY PN298SARS-CoV-1YSILMPILTLTRALAAESHMADAKPLIKWDLLKYDFTERLCLFDRYFKYWDQTY PN297Civet-CoVYSILMPILTLTRALAAESHMADAKPLIKWDLLKYDFTERLCLFDRYFKYWDQTY PN297Pangolin-CoVYSILMPILTLTRALAAESHMADAKPLIKWDLLKYDFTERLCLFDRYFKYWDQTY PN297SARS-CoV-2YSILMPILTLTRALTAESHVDTDTKPYIKWDLLKYDFTERLCLFDRYFKYWDQTY PN297Wuhan_Std-CoVYSILMPILTLTRALTAESHVDTDTKPYIKWDLLKYDFTERLCLFDRYFKYWDQTY PN297Bat_RaTG13-CoVYSILMPILTLTRALTAESHVDTDTKPYIKWDLLKYDFTERLCLFDRYFKYWDQTY PN297Wuhan_Std-CoVYSILMPILTTRALTAESHVDTDTKPYIKWDLLKYDFTERLCLFDRYFKYWDQTY PN297Bat_RATG13-CoVYSILMPILTTRALTAESHVDTDTKPYIKWDLLKYDFTERLCLFDRYFKYWDQTY PN297WERS-CoVCVNCTDDRCVLHCANFNVLFAMTMPKTCFGPIVRKIFVDGVPFVVSTCYHYKELGLVMM358SARS-CoV-1CINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357Civet-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357SARS-COV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSF	Wuhan_Std-CoV		237
MERS-CoVYSYLMPVLSMTDC LAAETHR CCP NKPLIEWPLTEYDFTD YKVQLFEKYFKYWDQTYEAN298SARS-CoV-1YSILMPILTITRA LAAESHMOAD LAKPLIKWDLLKYDFTEERLQLFDRYFKYWDQTYEPN297Civet-CoVYSILMPILTITRA LAAESHMOAD LAKPLIKWDLLKYDFTEERLQLFDRYFKYWDQTYEPN297Pangolin-CoVYSILMPILTITRA LAAESHMOAD LAKPLIKWDLLKYDFTEERLQLFDRYFKYWDQTYEPN297SARS-CoV-2YSILMPILTITRA LTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297Wuhan_Std-CoVYSILMPILTITRA LTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297Bat_RaTG13-CoVYSILMPILTITRA LTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297Bat_RaTG13-CoVYSILMPILTITRA LTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297Civet-CoVCVNCTDDRCVLHCANFNVLFAMTMPKTCFGPIVRKIFVDGVPFVVSCFYHYKELGVVHNQ357Civet-CoVCINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTFYHFRELGVVHNQ357Pangolin-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357Muhan_Std-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357Bat_RaTG13-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357Bat_RaTG13-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357Bat_RATG13-COVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357	Bat_RaTG13-CoV		237
SARS-CoV-1YSILMPILTLTRALAAESHMUADLAKPLIKWDLLKYDFTEERLCLFDRYFKYWDQTYEPN297Civet-CoVYSILMPILTLTRALAAESHMUADLAKPLIKWDLLKYDFTEERLCLFDRYFKYWDQTYEPN297Pangolin-CoVYSILMPILTLTRALAAESHWDDDLTKPYIKWDLLKYDFTEERLCLFDRYFKYWDQTYEPN297SARS-CoV-2YSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297Wuhan_Std-CoVYSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297Bat_RATG13-CoVYSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297WERS-CoVCVNCTDDRCVLHCANFNVLFAMTMPKTCFGPIVRKIFVDGVPFVVSCGVHYKELGLVMNM358SARS-CoV-1CINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSCGVHYKELGLVMNQ357Civet-CoVCINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGVHFRELGVVHNQ357Pangolin-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGVHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGVHFRELGVVHNQ357Bat_ATG13-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGVHFRELGVVHNQ357Bat_ATG13-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGVHFRELGVVHNQ357Bat_ATG13-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGVHFRELGVVHNQ357		**************************************	
SARS-CoV-1YSILMPILTLTRALAAESHMUADLAKPLIKWDLLKYDFTEERLCLFDRYFKYWDQTYEPN297Civet-CoVYSILMPILTLTRALAAESHMUADLAKPLIKWDLLKYDFTEERLCLFDRYFKYWDQTYEPN297Pangolin-CoVYSILMPILTLTRALAAESHWDDDLTKPYIKWDLLKYDFTEERLCLFDRYFKYWDQTYEPN297SARS-CoV-2YSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297Wuhan_Std-CoVYSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297Bat_RATG13-CoVYSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297WERS-CoVCVNCTDDRCVLHCANFNVLFAMTMPKTCFGPIVRKIFVDGVPFVVSCGVHYKELGLVMNM358SARS-CoV-1CINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSCGVHYKELGLVMNQ357Civet-CoVCINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGVHFRELGVVHNQ357Pangolin-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGVHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGVHFRELGVVHNQ357Bat_ATG13-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGVHFRELGVVHNQ357Bat_ATG13-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGVHFRELGVVHNQ357Bat_ATG13-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGVHFRELGVVHNQ357	MEDG C-M		2.0.0
Civet-CoVYSILMPILTLTRALAAESHMUADLAKPLIKWDLLKYDFTEERLCLFDRYFKYWDQTYEPN297Pangolin-CoVYSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297SARS-CoV-2YSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297Wuhan_Std-CoVYSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297Bat_RATG13-CoVYSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYEPN297Wers-CoVCVNCTDDRCVLHCANFNVLFAMTMPKTCFGPIVRKIFVDGVPFVVSCGYHYKELGLVMNM358SARS-CoV-1CINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357Civet-CoVCUNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357Bat_AATG13-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357Bat_AATG13-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357			
Pangolin-CoVYSILMPILT LTRALTAESHV DTD_TKPYIKWDLLKYDFT ERLKLFDRYFKYWDQTY PN297SARS-CoV-2YSILMPILT LTRALTAESHVDTDLTKPYIKWDLLKYDFTERLKLFDRYFKYWDQTY PN297Wuhan_Std-CoVYSILMPILT LTRALTAESHVDTD_TKPYIKWDLLKYDFTERLKLFDRYFKYWDQTY PN297Bat_RaTG13-CoVYSILMPILT LTRALTAESHVDTD_TKPYIKWDLLKYDFTERLKLFDRYFKYWDQTY PN297MERS-CoVCVNCTDDRCVLHCANFNVLFAMTMPKTCFGPIVRKIFVDGVPFVVSCCYHYKELGLVMNM358SARS-CoV-1CINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357Civet-CoVCUNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357Bat_ATG13-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTCYHFRELGVVHNQ357			
SARS-CoV-2YSLLMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYHPN297Wuhan_Std-CoVYSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYHPN297Bat_RaTG13-CoVYSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYHPN297*****:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:			
Wuhan_Std-CoVYSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTERLELFDRYFKYWDQTYEPN297Bat_RaTG13-CoVYSILMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTERLELFDRYFKYWDQTYEPN297******:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*		~	
Bat_RaTG13-CoV YSILMPILT_LTRALTAESHV_DTD_TKPYIKWDLL_KYDFT_ERLELFDRYFKYWDQTYPPN 297 MERS-CoV CVNCTDDRCVLHCANFNVLFAMTMPKTCFGPIVRKIFVDGVPFVVSCGYHYKELGLVUNM 358 SARS-CoV-1 CINCLDDRCILHCANFNVLFAMTMPKTCFGPIVRKIFVDGVPFVVSCGYHYKELGLVUNM 357 Civet-CoV CINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 Pangolin-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 SARS-CoV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 Wuhan_Std-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 Bat_ATG13-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357		~	
*** *** ***** *** ***** *** ***** *** ***** *** ***** *** ***** *** ***** *** ***** **** **** **** **** <td>_</td> <td>~</td> <td></td>	_	~	
MERS-CoV CVNCTDDRCVLHCANFNVLFAMTMPKTCFGPIVRKIFVDGVPFVVSCGYHYKELGLVMNM 358 SARS-CoV-1 CINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 Civet-CoV CINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 Pangolin-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 SARS-CoV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 Wuhan_Std-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 Bat_AaTG13-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357		~	
SARS-CoV-1 CINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTSYHFRELGVVHNQ 357 Civet-CoV CINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTSYHFRELGVVHNQ 357 Pangolin-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTSYHFRELGVVHNQ 357 SARS-CoV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTSYHFRELGVVHNQ 357 Wuhan_Std-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTSYHFRELGVVHNQ 357 Bat_aTG13-CoV CVNCLDDRCILHCANFNVLFSTVFPTSFGPLVRKIFVDGVPFVVSTSYHFRELGVVHNQ 357			
Civet-CoVCINCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357Pangolin-CoVCVNCLDDRCILHCANFNVLFSTVFPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357SARS-CoV-2CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357Wuhan_Std-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357Bat_RaTG13-CoVCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ357	MERS-CoV	CVNCTDDRCVLHCANFNVLFAMTMPKTCFGPIVRKIFVDGVPFVVSCGYHYKELGLV4NM	
Pangolin-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTFYHFRELGVVHNQ 357 SARS-CoV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 Wuhan_Std-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 Bat_LaTG13-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357			
SARS-CoV-2 CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 Wuhan_Std-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357 Bat_LaTG13-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQ 357			
Wuhan_Std-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTFYHFRELGVVHNQ 357 Bat_RaTG13-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTFYHFRELGVVHNQ 357			
Bat_RaTG13-CoV CVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTFYHFRELGVVHNQ 357			
	_		
	Bat_RaTG13-CoV		35/

Palanivelu; IJBCRR, 29(10): 29-52, 2020; Article no.IJBCRR.64238

SARS-CoV-1	DVSLHRHRLSLKELMYAADPAMHIASSNAFLDLRTSCFSVAALT $FGLFQTVRPGNP$	418
	DVNLHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVAALTNNVAFQTVKPGNFNK	417 417
Civet-CoV Pangolin-CoV	DVNLHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVAALTNNVAFQTVKPGNFNK DVNLHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVAALTNNVAFQTVKPGNFNK	417
SARS-CoV-2	DVNLHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVAALTNNVAFQTVKPGNFNK	417
Wuhan_Std-CoV	DVNLHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVAALTNNVAFQTVKPGNFNK	417
Bat_RaTG13-CoV	DVNLHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVAALTNNVAFQTVKPGNFNK **.** ***:*****************************	417
MERS-CoV	<mark>dfyd</mark> fvyskgffkegssvtlkhfffaqdgnaait <mark>dyn</mark> yysynlptmcdikqmlf¢mevvn	478
SARS-CoV-1 Civet-CoV	DFYDFAVSKGFFKEGSSVELKHFFFAQDGNAAISDYDYYRYNLPTMCDIRQLLFVVEVVD DFYDFAVSKGFFKEGSSVELKHFFFAQDGNAAISDYDYYRYNLPTMCDIROLLFVVEVVD	477 477
Pangolin-CoV	DFYDFAVSKGFFKEGSSVELKHFFFAQDGNAAISDIDIINUNDIIMEDINQLLFVVVVD	477
SARS-CoV-2	DFYDFAVSKGFFKEGSSVELKHFFFAQDGNAAISDYDYYRYNLPTMCDIRQLLFVVEVVD	477
Wuhan_Std-CoV Bat RaTG13-CoV	DFYDFAVSKGFFKEGSSVELKHFFFAQDGNAAISDYDYYRYNLPTMCDIRQLLFVVEVVD DFYLFAVSKGFFKEGSSVELKHFFFAQDGNAAISDYDYYRYNLPTMCDIROLLFVVEVVD	477 477
Bat_KaiGis-Cov	**************************************	4 / /
MERS-CoV	kyfelydggclnasevvvnnldksagh fnkfgkarvyyesmsyq <mark>eqd</mark> elfamtkrnvip	538
SARS-CoV-1	KYFDCYDGGCINANQVIVNNLDKSAGF PFNKWGKARLYYDSMSYE <mark>DQD</mark> ALFAYTKRNVIP	537
Civet-CoV Pangolin-CoV	KYFD¢YDGGCINANQVIVNNLDKSAGF PFNKWGKARLYYDSMSYE <mark>DQD</mark> ALFAYTKRNVIP KYFD¢YDGGCINANQVIVNNLDKSAGF PFNKWGKARLYYDSMSYEDQDALFAYTKRNVIP	537 537
SARS-CoV-2	KYFDCYDGGCINANQVIVNNLDKSAGFPFNKWGKARLYYDSMSYEDQDALFAYTKRNVIP	537
Wuhan_Std-CoV	KYFDCYDGGCINANQVIVNNLDKSAGF PFNKWGKARLYYDSMSYEDQDALFAYTKRNVIP	537
Bat_RaTG13-CoV	KYFDCYDGGCINANQ/IVNNLDKSAGF PFNKWGKARLYYDSMSYEDQDALFAYFKRNVIP ****: ****:********************************	537
MERS-CoV	TMTQMNLKYAISAKNRARTVAGVSILSTMTN <mark>RQY</mark> HQ <mark>K×L</mark> KSMAATRGATCVIGTTKF <mark>YGG</mark>	598
SARS-CoV-1	TITQMNLKYAISAKNRARTVAGVSIC\$TMTN <mark>RQF</mark> HQ <mark>KLL</mark> KSIAATRGATVVIGTSKF <mark>IG</mark> G	597
Civet-CoV Pangolin-CoV	TITQMNLKYAISAKNRARTVAGVSIC\$TMTN <mark>RQF</mark> HQ <mark>KLL</mark> KSIAATRGATVVIGTSKFY <mark>GG</mark> TITQMNLKYAISAKNRARTVAGVSIC\$TMTNRQFHQKLLKSIAATRGATVVIGTSKFYGG	597 597
SARS-CoV-2	TITQMNLKYAISAKNRARTVAGVSICSTMTNRQFHQKLLKSIAATRGATVVIGTSKFYGG	597 K574
Wuhan_Std-CoV	TITQMNLKYAISAKNRARTVAGVSIC\$TMTN <mark>RQF</mark> HQ <mark>KLL</mark> KSIAATRGATVVIGTSKF <mark>IGG</mark>	597
Bat_RaTG13-CoV	TITOMNLKYAISAKNRARTVAGVSICSTMTN <mark>ROF</mark> HO <mark>KLL</mark> KSIAATRGATVVIGTSKF [*] GG *:*********************************	597Y21,R-5
MERS-CoV	WDFMLKTLYKDVD PHLMGWDYPKCDRAMPNMCRIFASLILARKHGTCCTTRDRFYRLAN	658
SARS-CoV-1	WHNMLKTVYS <mark>DVE</mark> CPHLMGWDYPKCDRAMPNMLRIMASLVLARKHNTCCNLSHRFYRLAN	657
Civet-CoV Pangolin-CoV	WHNMLKTVYS DVECPHLMGWDYPKCDRAMPNMLRIMASLVLARKHNTCCNLSHRFYRLAN WHNMLKTVYS DVENPHLMGWDYPKCDRAMPNMLRIMASLVLARKHTTCCSLSHRFYRLAN	657 657
SARS-CoV-2	WHNMLKTVYSDVENPHLMGWDYPKCDRAMPNMLRIMASLVLARKHTTCCSLSHRFYRLAN	657
Wuhan_Std-CoV	WHNMLKTVYSDVENPHLMGWDYPKCDRAMPNMLRIMASLVLARKHTTCCSLSHRFYRLAN	657
Bat RaTG13-CoV		
	WHNMLKTVYS DVENPHLMGWDYPKCDRAMPNMLRIMASLVLARKHTTCCSLSHRFYRLAN *. ****:*******************************	657
- MERS-CoV	*. ****:*. ***. ***********************	657 718
— MERS-CoV SARS-CoV-1	*. ****:*. **:. ***********************	657 718 717
- MERS-CoV SARS-CoV-1 Civet-CoV	*. ******* **** **********************	657 718 717 717
— MERS-CoV SARS-CoV-1	*. ****:* ***: ************************	657 718 717
- MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV <mark>SARS-CoV-2</mark> Wuhan_Std-CoV	*. ****:* ***: ************************	657 718 717 717 717 717 717 N691 717
- MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2	*. ****:* ***: ************************	657 718 717 717 717 717 N691
- MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV <mark>SARS-CoV-2</mark> Wuhan_Std-CoV	*. ******* ***************************	657 718 717 717 717 717 717 N691 717
- MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1	*. ****** ****************************	657 718 717 717 717 717 717 717 717 717 71
- MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV	*. ****** ****************************	657 718 717 717 717 717 717 717 717 717 71
- MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1	*. ****** ****************************	657 718 717 717 717 717 717 717 717 717 777 77
- MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV	*. ****** ****************************	657 718 717 717 717 717 717 717 717 778 777 777
- MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2	*. ****** ****************************	657 718 717 717 717 717 717 717 717 717 778 777 777
- MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV	*. ****** ****************************	657 718 717 717 717 717 717 717 717 778 777 777
MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1	*. ****** *** *** ********************	657 718 717 717 717 717 717 717 71
MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV	*. ****** ****************************	657 718 717 717 717 717 717 717 717 717 71
MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV	*. ****** *** *** ********************	657 718 717 717 717 717 717 717 71
MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV	*. ****** ****************************	657 718 717 717 717 717 717 717 717 717 71
MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2 Wuhan_Std-CoV Bat_RaTG13-CoV MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2	*. ****** ****************************	657 718 717 717 717 717 717 717 71

Palanivelu; IJBCRR, 29(10): 29-52, 2020; Article no.IJBCRR.64238

MERS-CoV SARS-CoV-1 Civet-CoV Pangolin-CoV SARS-CoV-2	LSAGCFVDDIVKTDGTLMVERFVSLAIDAYPLTKHEDIEYQNVFWVYLQYIEKLYKDLTG LGAGCFVDDIVKTDGTLMIERFVSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTG LGAGCFVDDIVKTDGTLMIERFVSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTG LGAGCFVDDIVKTDGTLMIERFVSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTG LGAGCFVDDIVKTDGTLMIERFVSLAIDAYPLTKHPNOEYADVFHLYLQYIRKLHDELTG	898 897 897 897 897
Wuhan Std-CoV	LGAGCFVDDIVKTDGTLMIERFVSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTG	897
Bat RaTG13-CoV	LGAGCF <mark>VDD</mark> IVKTDGTLMIERFVSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTG	897
_	*.**** <mark>***</mark> ****************************	
MERS-CoV	HMLDSYSVMLCGDNSAKFWEEAFYRDLYSSPTTLQ 933	
SARS-CoV-1	HMLDMYSVMLTNDNTSRYWEPEFYEAMYTPHTVLQ 932	
Civet-CoV	HMLDMYSVMLTNDNTSRYWEPEFYEAMYTPHTVLQ 932	
Pangolin-CoV	HMLDMYSVMLTNDNTSRYWEPEFYEAMYTPHTVLQ 932	
SARS-CoV-2	HMLDMYSVMLTNDNTSRYWEPEFYEAMYTPHTVLQ 932	
Wuhan_Std-CoV	HMLDMYSVMLTNDNTSRYWEPEFYEAMYTPHTVLQ 932	
Bat_RaTG13-CoV	HMLDMYSVMLTNDNTSRYWEPEFYEAMYTPHTVLQ 932	
_	**** ***** .**:: :** **. :*: *. **	



CLUSTAL O (1.2.4) MSA of primases (NSP8)

MERS_CoV	ATLSEFSHLATFAELEAAQKAYQEAMDSGDTSPQVLKALQKAVNIAKNAY <mark>EKD</mark> KAVARKL	60
SARS_CoV-2	AIASEFSSLPSYAAFATAQEAYEQAVANGDS-EVVLKKLKKSLNVAKSEFDRDAAMQRKL	59 K58/SDM
Wuhan_Ref CoV-2	AIASEFSSLPSYAAFATAQEAYEQAVANGDS-EVVLKKLKKSLNVAKSEF <mark>DRD</mark> AAMQ <mark>RK</mark> L	59
Bat_RaTG13_CoV	AIASEFSSLPSYAAFATAQEAYEQAVANGDS-EVVLKKLKKSLNVAKSEF <mark>DRD</mark> AAMQ <mark>RK</mark> L	59
Pangolin_CoV	AIASEFSSLPSYAAFATAQEAYEQAVANGDS-EVVLKKLKKSLNVAKSEFDRDAAMQRKL	59
SARS_CoV-1	AIASEFSSLPSYAAYATAQEAYEQAVANGDS-EVVLKKLKKSLNVAKSEF <mark>DRD</mark> AAMQ <mark>RK</mark> L	59
Civet_CoV	AIASEFSSLPSYAAYATAQEAYEQAVANGDS-EAVLKKLKKSLNVAKSEFDRDAAMQRKL * **** * ::* :**:*:*: *** *:**: *** *:*:*:*** ::*:**** *:******	59
MERS CoV	ERMADQAMTSMYKQARAEDKKAKIVSAMQTMLFGMIKKLDNDVLNGIISNARNGCIPLSV	120
SARS CoV-2	EKMADOAMTOMYKOARSEDKRAKVTSAMOTMLFTMLRKLDNDALNNIINNARDGCVPLNI	119 R75
Wuhan Ref CoV-2	EKMADOAMTOMYKOARSEDKRAKVTSAMOTMLFTMLRKLDNDALNNIINNARDGCVPLNI	119
Bat RaTG13 CoV	EKMADOAMTOMYKOARSEDKRAKVTSAMOTMLFTMLRKLDNDALNNIINNARDGCVPLNI	119
Pangolin CoV	EKMADQAMTQMYKQARSEDKRAKVTSAMQTMLFTMLRKLDNDALNNIINNARDGCVPLNI	119
SARS CoV-1	EKMADOAMTOMYKOARSEDKRAKVTSAMOTMLFTMLRKLDNDALNNIINNARDGCVPLNI	119
Civet CoV	EKMADQAMTQMYKQARSEDKRAKVTSAMQTMLFTMLRKLDNDALNNIINNARDGCVPLNI	119
	* : * * * * * * * • • * * * • • * * •	
MERS CoV		
		170
	IPICASNKIRVVIPDFTVWNQVVTYPSLNYAGALWDITVINNVDWEIVKSSDV-VDSNEN	179
SARS_CoV-2	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN	<mark>179</mark> К127/Ү149
SARS_CoV-2 Wuhan_Ref CoV-2	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFT <mark>YASA</mark> LWEIQQVVP <mark>ADS</mark> KIVQLSEISMDNSPN	179 K127/Y149 179 Y23
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFT <mark>YASA</mark> LWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFT <mark>YASA</mark> LWEIQQVVDADSKIVQLSEISMDNSPN	179 K127/Y149 179 Y23 179
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN	179 K127/Y149 179 Y23 179 179
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV SARS_CoV-1	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPN	179 K127/Y149 179 Y23 179 179 179
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPN	179 K127/Y149 179 Y23 179 179
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV SARS_CoV-1	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPN	179 K127/Y149 179 Y23 179 179 179
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV SARS_CoV-1	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPN	179 K127/Y149 179 Y23 179 179 179
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV SARS_CoV-1 Civet_CoV	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVPDYGTYKNTCDGNTFTYASALWEIQUVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVPDYGTYKNTCDGNTFTYASALWEIQUVVDADSKIVQLSEISMDNSPN	179 K127/Y149 179 Y23 179 179 179
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV SARS_CoV-1 Civet_CoV MERS_CoV	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAALIMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAALIMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKIMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKIMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKIMVVPPDYGTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKIMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPN IPITTAAKIMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPN *** :: ** **: ::::::::::::::::::::::::::::	179 K127/Y149 179 Y23 179 179 179
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV SARS_CoV-1 Civet_CoV MERS_CoV SARS_CoV-2	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPN IPITTAAKLMVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPN *** :: ** **:*: ::::::::::::::::::::::::::	179 K127/Y149 179 Y23 179 179 179
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV SARS_CoV-1 Civet_CoV MERS_CoV SARS_CoV-2 Wuhan_Ref CoV-2	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVPDYGTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVPDYGTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPN *** :: ** **: *:: :: :: :: **: *:: :: **: *:: :*: *:	179 K127/Y149 179 Y23 179 179 179
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV SARS_CoV-1 Civet_CoV MERS_CoV SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKIMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKIMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKIMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKIMVVPDYGTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKIMVVPDYGTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKIMVVPDYGTYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPN *** :: ** *** :: ** *** :: ** *** :: ** LTWPLVLECTRAFTSAVKLQ 199 LAWPLIVTALRANS-AVKLQ 198 LAWPLIVTALRANS-AVKLQ 198 LAWPLIVTALRANS-AVKLQ 198	179 K127/Y149 179 Y23 179 179 179
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV SARS_CoV-1 Civet_CoV MERS_COV SARS_COV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPN *** :: ** *** :: ** *** :: ** *** :: ** *** :: ** *** :: ** LTWPLVLECTRASTSAVKLQ 199 LAWPLIVTALRANS-AVKLQ 198 LAWPLIVTALRANS-AVKLQ 198 LAWPLIVTALRANS-AVKLQ 198 LAWPLIVTALRANS-AVKLQ 198 LAWPLIVTALRANS-AVKLQ 198	179 K127/Y149 179 Y23 179 179 179
SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV SARS_CoV-1 Civet_CoV MERS_CoV SARS_CoV-2 Wuhan_Ref CoV-2 Bat_RaTG13_CoV Pangolin_CoV SARS_CoV-1	IPLTTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEISMDNSPN IPITTAAKLMVVVPDYGYKNTCDGNTFTYASALWEIQQVVDADSKIVQLSEINMDNSPN *** :: *** :: *** :: *** :: *** :: *** :: *** :: *** :: *** :: *** :: *** :: *** :: *** :: LTWPLVIECTRA\$TSAVKLQ 198 LAWPLIVTALRANS-AVKLQ 198 LAWPLIVTALRANS-AVKLQ 198 LAWPLIVTALRANS-AVKLQ 198 LAWPLIVTALRANS-AVKLQ 198	179 K127/Y149 179 Y23 179 179 179

Fig. 6. MSA analysis of primases (NSP8) in SARS and SARS-related CoVs

Interestingly, in primases also the SARS-CoV-1 and palm civet-CoV-1 sequences are very close to each other (marked in magenta, Fig. 6) as found in the spike proteins. [7].

Fig. 7 shows the MSA analysis of the NSP7 which is found to be associated with the SARS-CoV RdRp-primase complex. Only the N-terminal region is highly conserved in all but the C-

terminal region is also conserved in all except in MERS-CoV NSP7 subunit. The -LQ diad appears to be the protease cleavage point during the polyprotein processing and is completely conserved in all. As there are no template binding YG or YA pairs as seen in the RdRps and primases, this subunit may possibly play only supportive role in the replication process. Its purely supportive role has been further proved by mutational analysis too. For example, Subissi et al. [37] have shown that several mutations in the NSP7 subunit did not affect the viral replication to any significant level.

3.3 Analyses of Active Site Amino Acids in Various Domains of RdRps of RNA Viruses


Unlike other viral RdRps, RdRps of CoVs are composed of four distinct domains, viz. NiRAN, Fingers Palm, and Thumb. The polymerase domains, viz. fingers, palm and thumb are made up of three sets of highly/completely conserved amino acid(s)/motif(s) which perform distinct but highly coordinated functions during polymerization process [22,23]. The viral RdRps from both (–) and (+) strand viral pathogens are extensively studied by various investigators as they are the primary drug target to control the viral multiplication [37].

Cryo-EM analysis of the CoV-2 RdRp with 932 amino acids, has shown that the amino acids from 1-397 form the NiRAN domain including an interface and the rest of the protein from 398-932 form the RdRp. The NiRAN domain from the Nterminal is followed by an interface which connects the RdRp [17]. In RdRp, approximately amino acids from 398-580 form the fingers, 581-812 form the palm including an interface of ~60 amino acids and 813-932 form the thumb domains [17] (Fig. 8). All these domains are interconnected for effective coordination, e.g., the finger domain loops interconnect the fingers with the thumb domain and the NTP and template entry channels meet at the palm domain. Possible catalytic amino acid motifs and catalytic amino acids of various domains of SARS-CoV-2 RdRp are presented in Fig. 8.


3.3.1 Analysis of the NiRAN domain


NiRAN, Nidovirus RdRp-Associated Nucleotidyltransferase domain is a unique domain found only in SARS and SARS-related CoVs RdRps and with no apparent viral or cellular homologues making it a second genetic marker for the order Nidovirales. It exhibits a dual specificity for UTP and GTP. Furthermore, it is shown to be an essential domain of all RdRps of Nidoviruses. An invariant K, i.e., the K⁷³ in all SARS-CoV RdRps and K⁷⁵ in MERS-CoV RdRp, was found in the conserved motif of this domain (marked in red) and its importance discussed elsewhere.

CLUSTAL O (1.2.4) MSA of NSP7 of the primase complex









Replacement of the $K^{73} \rightarrow A$ by SDM experiments has shown that the viral RdRp (equine arteritis) lost its replication activity in cell culture studies. In addition to its role in replication, other important functions are also implicated for this domain, such as ATPdependent RNA ligase, mRNA capping (guanylyltransferase), UTP/GTP binding and nucleotidylation, and protein-primed RNA synthesis, etc. [33]. Interestingly, the N-terminal of the polio residues viral RdRp also exhibited strong interaction with the Cterminal thumb region. The N-terminal residues are found to be essential for polymerase activity; deletion of Trp5 or of residues 1-6 completely inactivates the polio viral RdRp activity. In CoV-2 this region is shown to interact with the base of the polymerase palm and fingers domains [27].

3.3.2 Fingers domain

Amino acids from 398 to 580 form the fingers domain. It is a nucleotide interacting domain which primarily involves in NTP bindina and selection in nucleic acid polymerases (Fig. 8). NTP and dNTP discrimination in nucleic acid polymerases is usually achieved by base pairing, base stacking, hydrogen bonding and by specific interaction(s) of the completely conserved basic amino acid (R/K/H) very close to the catalytic amino acid. Thus, NTP binding and selection is usually achieved by a basic amino acid which is placed very close to the catalytic amino acid in the downstream region. The invariant R/K/H is usually placed at -4 to -6 from the catalytic amino acid K/R and is also shown to be crucial for DNA and RNA polymerases (Table 1) [22,23]. Furthermore, this domain also harbours the catalytic amino acid, an invariant K/R in the catalytic region. Moreover, this domain is made up of many highly conserved, positively-charged basic amino acids and hydroxyl amino acids such as S/T in the highly conserved block preceding the NTP binding and catalytic amino acids (Fig. 5). Interestingly, this region is particularly devoid of any acidic amino acids like D or E. The Incoming NTPs would enter the active site through a tunnel at the back of this domain.

3.3.3 Palm domain

Amino acids from 581 to 812 including an interface region of ~60 amino acids form the

palm domain (Fig. 8). This domain primarily contains the template binding YG pair and a nucleotide discrimination motif (highlighted in yellow). The MSA analysis shows that amino acids K and Y from $K^{574}L$ to $Y^{595}G$ pairs are likely to play a role in catalysis as reported for DdDps. In support of this MSA finding, the cryo-EM analysis also found that the proposed Y⁵⁹⁵ in the palm domain of CoV-2 RdRp. The cryo-EM study has also found the amino acids G⁵⁹⁰ and S⁵⁹² in the conserved block preceding the YG pair [17]. These findings are further supported by Wang et al [2] who investigated the molecular basis of SARS-CoV-2 RNA replication by analyzing the cryo-EM structures of the stalled pre- and posttranslocated polymerase complexes. They found in the pre-translocated complex N496, K500, S501, N507, and K577 from the fingers domain and Y⁵⁹⁵ from the palm domain directly participating in stabilizing the phosphate backbone of the template. An invariant template binding YG pair is also shown to be in the palm domain of DNA and RNA polymerases [22,23]. It is interesting to note that in all SARS CoVs the completely and SARS-related conserved template binding YG pair (highlighted in yellow) is found in a completely conserved block (Fig. 5). Thus, the invariant YG pair appears to be specific not only for the nucleic acid polymerases using DNA as the template (including the viral type SSU and prokaryotic and eukarvotic MSU DdRps (Table 1) but also RNA as template (RdRps).

Not only the Y but also the G in the YG pair was found to be essential for polymerase function. A point mutation $G^{294} \rightarrow A$ in the palm domain of the RdRp of the encephalomyocarditis virus (corresponds to the amino acid is G^{767} in the YG pair in *E. coli* DNA polymerase I) completely lost the activity. Another point mutation at $Y^{293} \rightarrow T$ of the YG pair in the same viral RdRp (corresponds to Y^{766} of the YG pair in *E. coli* DNA polymerase I which involves in the dNTP binding at 3-end of primer) showed only 6% activity [29].

In addition to, Hillen et al. [17] [2020] have found Y^{689} and N^{691} in the highly conserved –YAN- motif (highlighted in yellow) is also in the active site region of the palm domain. They found D^{760} , D^{761} of the –SDD- motif and N^{691} of the –YAN- motif in the active site. $D^{760} \rightarrow A$ mutation was incapable of RNA synthesis even in the presence of NSP7 and NSP8. Therefore, it was proposed that both Y^{689} and N^{691} (of the YAN motif) found at the active site, to recognize the 2'-OH group of the incoming NTP and thus, involve in the nucleotide

Table 1. Amino acids around the catalytic amino acid K/R and the YG/FG pair in DNA/RNA polymerases and SARS-CoV RdRps

Polymerase Type	Catalytic Region
SSU RNA and DNA Polymerase	<u>s</u>
Viral T7 SSU RNA pol Viral SP6 SSU RNA Pol Mitochondrial SSU RNA pol (Yeast) Chloroplast SSU pol (ARATH) <i>E. coli</i> DNA pol I (SSU)	- ₆₂₀ WLAYGVTR ⁻⁵ SVTKR ¹ SVMTLAY ⁸ GS- - ₆₁₂ WDSIGITR ⁻⁵ SLTKK ¹ PVMTLP <mark>Y⁸GS</mark> - -TR ⁻⁵ KVVKQ ¹ TVMTNVY ⁸ GV -DR ⁻⁵ KLVKQ ¹ TVMTSVY ⁸ GV- -QR ⁻⁵ RSAKA ¹ INFGLIY ⁸ GM-
Initiation Subunits of Prokaryo	tic and Eukaryotic MSU RNAPs
<i>E. coli</i> MSU RNAP β subunit <i>S. cerevisiae</i> MSU RNAP II Rpb2 sul Human MSU RNAP II Rpb2 subunit	-539 TR⁻⁸ERAGFEVRD¹VHPTHY⁷G⁸RV 558- bunit
Elongation Subunits of Prokar	yotic and Eukaryotic MSU RNAPs
<i>E. coli</i> MSU RNAP β' subunit <i>S. cerevisiae</i> MSU RNAP II Rpb1 sul Human MSU RNAP II Rpb1 subunit	- ₈₃₃ NSV ⁻⁶ DAVKVRS ¹ VVSC ⁵ DTDFGVC ¹² AHC ¹⁵ Y ¹⁶ G ¹⁷ RDL ₈₆₁ - bunit ₋₅₅ DPR ⁻⁶ LGSIDRN ¹ LKC ⁴ QTC ⁷ QEGMNEC ¹⁴ PGHF ¹⁸ G ¹⁹ HI ₈₄ - ₋₅₉ DPR ⁻⁶ QGVIERT ¹ GRC ⁴ QTC ⁷ AGNMTEC ¹⁴ PGHF ¹⁸ G ¹⁹ HI ₈₈ -
SARS-Related CoVs*	
RdRPs (NSP12)	
SARS-CoV-2 -STN	ΛΤΝ <mark>R⁻⁵QFHQ<mark>KL</mark>¹LKSIAATRGATVVIGTSKF<mark>Y²¹G</mark>G597- ΛΤΝ<mark>R⁻⁵QFHQKL¹LKSIAATRGATVVIGTSKFY²¹G</mark>G597- ΛΤΝ<mark>R⁻⁵QYHQKM¹LKSMAATRGATCVIGTTKFY²¹G</mark>G598-</mark>
NiRAN Nucleotidyl-transferase -	₁₁₂ PH ⁻⁵ IS <mark>R⁻²QRL</mark> ¹ TKYTMADLV <mark>Y¹¹AL₁₃₁-</mark>
<u>Primases (NSP8)*</u>	
SARS-CoV-2	. ₁₂₀ IPLTTAA <mark>KL¹</mark> MVVVPDYGTYKNTCDGNTFT <mark>Y²²AS</mark> ALWE- . ₁₂₀ IPLTTAA <mark>KL¹</mark> MVVIPDYNTYKNTCDGTTFT <mark>Y²²AS</mark> ALWE- . ₁₂₁ IPLCASN <mark>KL¹RVVIPDFTVWNQVVTYPSLNY²²AG</mark> ALWD-
Active Site Regions in Prokary	otic and Eukaryotic DNA Polymerases <mark>#</mark>
T4 DNA polymerase <i>P. furiosus</i> DNA polymerase Yeast alpha DNA polymerase Human alpha DNA polymerase Human Gamma DNA polymerase Human Delta DNA polymerase (Catalytic subunit)	- ₆₈₃ RQVLDG R⁻⁵QLAL<mark>KV</mark>¹SANSVY⁷G FTGAQV-
	ons of functionality to the completely conserved motifs is important in by experiments. #Adapted from Palanivelu [22]

discrimination by selecting NTPs and not dNTPs during RNA synthesis [17,2]. Therefore, the invariant YG pair and YAN motif found not only in CoV-2 RdRp but also in all SARS and SARS-related CoV RdRps are shown in nucleotide binding and selection in the proposed mechanism. Thus, the palm domain plays a role in template binding and could bind the negatively charged triphosphate backbone of the incoming NTP at position +1. Its triphosphate group is further stabilized by the catalytic Mg²⁺ that is coordinated by the palm domain.

3.3.4 Thumb domain

Amino acids from 813 to 932 in the C-terminal region form the thumb domain (Fig. 8). This domain is mostly formed by amino acids, viz. R836, K849, M855, E857, R858, S861, I864, D865, Y915. Interestingly, the stretch of amino acids from 840 to 872 forms the highly conserved region with–YLQYI⁸⁸⁸- diad repeat and highly conserved -HMLDMYSVML- and -YWE-motifs in all SARS and SARS-related CoV RdRps (a minor exception was observed in MERS-CoV RdRp) (Fig. 8).

The thumb domain primarily involves in correctly positioning the NTPs for the electrophilicpolymerization nucleophilic attack during reactions using their invariant Ds by forming Mg²⁺-NTP complex, e.g., two highly conserved Ds coordinate Mg²⁺ ions in the catalytic site in all DNA and RNA polymerases including the SARS-CoV RdRps (Fig. 5). The thumb domain of various nucleic acid polymerases has analyzed been extensively by X-ray crystallographic and SDM experiments. Biochemical, crystallographic and SDM analyses of many RdRps of (+) strand and (-) strand viruses have shown that the palm domain is mainly consisted of the crucial catalytic metal binding amino acids which usually bind a Mg²+ ion. These studies have unequivocally proved the presence of an invariant -GDD- motif which is known as the universal motif in all (+) strand viral RdRps [28]. This motif is also found in all SARS and SARS-related CoV RdRps as well (Fig. 5).

Sankar and Porter [29] analyzed the universal metal binding -GDDmotif in encephalomyocarditis (EMC) virus by SDM experiments. (a (+) strand, non-enveloped RNA virus, belonging to Picornaviridae, is the causative agent of not only myocarditis and encephalitis, but also neurological diseases, reproductive disorders and diabetes in many mammalian species) They found that all three amino acids in the -GDD- motif are essential for the RdRp activity. For example, replacements of $G^{332} \rightarrow A$; $D^{333} \rightarrow E D^{334} \rightarrow E$ vielded 0%. 3% and 0% activities of the enzyme. respectively.

X-ray crystallographic analysis of the RdRp of dengue virus (a (+) strand RNA viral human pathogen) clearly revealed the presence of one hydrated Mg²⁺ ion close to the expected catalytic position, hexa-coordinated by Asp-533 (-ADD⁵³³⁻) via a water molecule and by Asp-664 (-GDD⁶⁶⁴⁻) [32]. Interestingly, they also found that the -ADD- and -GDD- motifs are completely conserved in other (+) strand RNA viral pathogens' RdRps like Yellow fever virus, (YFV), Japanese encephalitis virus (JEV), and West Nile virus (WNV).

The functional role of –GDD- in catalysis is further corroborated by SDM analysis of the replicase of a (+) strand RNA viruses, the Q β bacteriophage and PV. The substitution of the G of the –GDD- sequence by A, S, P, M or V residues in Q β (C, P, M and V in PV) completely abolished the replicase activity [30,31], suggesting the importance of this universal motif in all RdRps including bacteriophages. Interestingly, this metal binding motif is also conserved in most viral RdRps, e.g., 317 to 319 (-GDD-) in HCV 3Dpol, ns5b and 327 to 329 (-GDD-) in PV RdRp.

The same motif is found in all SARS and SARsrelated CoV RdRps also (highlighted in dark green) (Fig. 5). In addition to this universal motif, Hillen el al and Wang et al [17,2] have also found another conserved motif the -SDD⁷⁶¹- in the active site of SARS-CoV-2 RdRp. Interestingly, this metal binding motif is common in (-) strand viral pathogens (Table 2). The completely conserved –GDD- and -SDD- motifs in SARS and SARS–related RdRps are highlighted in dark green (Fig. 5).

3.4 Analyses of Metal Binding Sites in RdRps of + and – Strand RNA Viral Pathogens

In order to find out whether both the types of viral pathogens use same type of metal biding sites, the RdRps of both (+) and (–) RNA viruses were analyzed by MSA analysis (this communication), and a consensus is arrived at using SDM experiments and X-ray crystallographic data.

Almost all the nucleic acid polymerases invariably are known to use two Ds for the binding of the catalytic Mg^{2+} ion (Table 2). The (+) strand viruses, including the CoVs, invariably use the two Ds possibly from one from the–GDDmotif and the other from the –SDD- motif. As already discussed Sankar and Porter [29] have shown the point mutations generated by SDM experiments in the metal binding motif -G³³²DDdrastically affected the polymerization activity of RdRp of EMC virus. Their results showed that all three amino acids are important in maintaining the structure at the metal (Mg²⁺) binding region (Table 2).

Not only the (+) strand RNA viruses but also the strand RNA viral pathogens such as influenza, measles, mumps and respiratory syncytial viruses and Ebola virus (EBOV) also use RdRp for genome replication and utilize Mg²⁺ as a cofactor for replication. However, MSA (this communication), SDM experiments and minigenome assays [38] have shown that -GDNQis an invariant motif in all the – strand RNA viruses like Ebola, Influenza, Rabies Measles and Mumps viral RdRps (Table 2). Schmidt and Hoenen [38] have found by SDM experiments that the $-GD^{742}NQ- \rightarrow -GAAA-$ mutation in Ebola viral RdRp abolished the replication as well as transcription activities. In addition to, they found by MSA analysis that the (-) strand RNA viral pathogens possessed the invariant -GDNQin their RdRps indicating that this motif is absolutely essential for genome replication, transcription, or both. Tchesnokov et al. [39] found that the $D^{742} \rightarrow A$ mutant in the $-GD^{742}NQ$ motif of Ebola viral RdRp lacked the ability to extend the primer in the presence of Mg²⁺ and therefore, it is clear that the Ebola viral RdRp mutant $D^{742} \rightarrow A$ abolishes the catalytic Mg⁴ binding activity and hence the enzyme activity too. In addition to this motif, the (-) strand viral pathogens also possess a regular -G/SDDmotif(s) as found in (+) strand viral RdRps (Table 2). It is clear from Table 2 that -GDD- and -GDN- are signature metal binding sites in (-) strand viral RdRps.

However, the MSU DdRps of both prokaryotic (eubacterial and chloroplasts) and eukaryotic organisms use a different metal binding sites like –E/DxD-, -NxEDS- (for initiation reaction) and -NADFDGD- (for elongation reaction) (Table 2) [24-26,40]. By electron paramagnetic resonance spectroscopy, flow-dialysis and transcription analysis, the D⁵³⁷ and D⁸¹² in bacteriophage T7 RNA polymerase were found to be as metal ion-binding sites and are found to be essential for the catalytic mechanism [41]. The metal binding sites of both DdRps and RdRps are shown in Table 2.

3.5 Mechanism of Action of the RdRp of SARS-CoV-2

It is interesting to note that all the observed structural features of DNA and RNA polymerases suggest not only a strong conservation of structure-function relationships among them, but also a very similar active site amino acids and catalytic mechanism [22-26]. A minimal number of steps involved in the catalytic cycle of RdRps are: NTP selection, Watson-Crick base pairing with the complementary nucleotide to the template, catalysis, pyrophosphate release and translocation. Catalysis is initiated by nucleophilic attack on the a-phosphate of the base-paired NTP on the primer 3'-OH leading to formation of the phosphodiester bond and subsequent release of the pyrophosphate. Based on all the data available on SARS-CoV-2, Fig. 9 describes

a plausible mechanism of action for the SARS-CoV-2 RdRp.

Step 1. Enzyme with the NTP at the Entry Site: Template binding by Y⁵⁹⁵-G pair, NTP binding and selection by the invariant amino acid(s) at the catalytic site. (The invariant R⁵⁶⁹ is shown to play the important role in NTP binding and selection as reported for other nucleic acid polymerases. The quanido group of R⁵⁶⁹ could form the necessary hydrogen bonding with the triphosphate group of the substrate in the ternary complex). Watson-Crick base pairing is performed of the incoming NTP with the template RNA. The catalytic site amino acid $K^{5/4}$ is positioned for proton abstraction. The Mg²⁺ which is coordinated by the catalytic D^{760} and D^{824} . which shields the β - and γ - phosphates and exposes the α -phosphate of NTPs for the nucleophilic attack at the polymerizing site. The second set of amino acids in the active site. viz. Y⁶⁸⁹ and N⁶⁹¹ in the completely conserved –YANmotif in all SARS and SARS-related CoV RdRps further reinforce the nucleotide discrimination by stacking interactions and recognizing the 2'-OH in the ribose moiety the NTPs. The Y is suggested to involve in base stacking as well as hydrogen bonding 2'-OH of ribose moiety and N is shown to recognize the 2'-OH of the of ribose mojety by hydrogen bonding. Thus, recognition of the 2'-OH of ribose moiety by Y and N becomes the major fidelity checkpoint here. YAN/Q type of motif is also found in the RdRps of Dengue, Zika, and Yellow Fever viruses too (data no shown).

Step 2. Proton Abstraction and Nucleophilic Attack of the α -phosphate of NTP: Electronic transition at the active site for proton abstraction by the active site K and for the initiation of electrophilic and nucleophilic attack.

Step 3. Phosphodiester Bond Formation: Proton abstraction by the active site amino acid K and simultaneous formation of phosphodiester bond. K/H is also proposed in the catalytic site of RdRp of PV to protonate the PPi leaving group during catalysis [36].

Step 4. Inorganic Pyrophosphate Formation and Translocation of the Enzyme to Next Nucleotide: Proton transfer from the active site amino acid K and formation of inorganic pyrophosphate; restoration of the active site and translocation of the enzyme to next nucleotide (Fig. 9).

Table 2. Metal bindir	g sites in DNA- and	RNA-dependent RN	IA polymerases
-----------------------	---------------------	------------------	----------------

Subunit (Organism)	Metal biding site(s)	Method and Reference
Eubacteria (MSU RNA p	pol)	
β- subunit (<i>E. coli</i>) β'- subunit, Elongation (<i>I</i> _ ⁸⁸³ F	- ⁶⁷¹ LEHDDA/ - ⁸⁰⁹ GYNFEDS*-(Mg ²⁺) E. co/i) - ⁴⁵⁸ YNADFDGDQM - (Mg ²⁺) & RS ¹ VVSC ⁵ DTDFGVC ¹² AHC ¹⁵ Y ¹⁶ GR ⁹⁰¹ -(Zn ²⁺)*	By MSA <mark>[24]</mark> By X-ray crystallography [40]
Eukaryote (MSU RNA p	ol)	
Rpb2 subunit (S. cerevis Rpb1 subunit, Elongation - ⁵⁶ PR ⁶ LG	siae) - ⁸⁹³ LDDDG ⁸⁹⁷ ⁸³² GYNQED*S ⁸³⁸ -(Mg ²⁺) n (<i>S. cerevisiae</i>)- ⁴⁷⁸ YNADFDGDEM ⁴⁸⁷ -(Mg ²⁺) SIDRN ¹ LKC ⁴ QTC ⁷ QEGMNEC ¹⁴ PGHF ¹⁸ GH ⁸³ -(& By MSA [25]
Chloroplast (MSU RNA	pol)	
$\begin{array}{ll} \beta \text{-subunit} & (\textit{Zea mays}) \\ \beta \text{'-subunit} & (\textit{Zea mays}) \\ \beta \text{''-subunit} & (\textit{Zea mays}) \end{array}$		By MSA [26]
Mitochondria (SSU RNA	<mark>A pol)</mark>	
Arabidopsis thaliana Nicotiana sylvestris S. cerevisiae Candida albicans Neurospora crassa	-QD ⁶⁷⁷ GSC- & -VH ⁹⁰⁸ DSF- -QD ⁷⁰³ GSC- & -VH ⁹³⁴ DSY- -QD ⁹⁴⁵ GTC- & -VH ¹¹⁸⁸ DSY- -QD ⁸⁸¹ GTC- & -VH ¹¹²¹ DSF- -QD ⁹⁰¹ GTC- & -VH ¹¹⁸⁰ DSF-	By MSA [23]
Chloroplast (SSU RNA	pol)	
Arabidopsis thaliana Brsassica napus	-QD ⁶⁹⁴ GSC- & -VH ⁹²⁵ DSY- -QD ⁶⁸⁰ GSC- & -VH ⁹¹² DSY-	
Bacteriophages (SSU R	NA pol)	
T7 phage Lambda Phage	-FD ⁵³⁷ GSC- & -HD ⁸¹² SFG- -FD ⁵³⁷ GSC- & -HD ⁸¹² SFG-	By EPR and FD [41] [23]
RdRps (EC 2.7.7.48) of ((+) Strand Viruses	
CoV-2 CoV-1 Polio Hepatitis C Dengue Zika Yellow Fever Rubella Encephalomyocarditis	-LSDD ⁷⁶¹ A- & -QGDD ⁸²⁵ Y- -LSD ⁷⁶⁰ DA- -YGDD ³²⁹ - NGDD ³¹⁹ - -YADD ⁵³³ TA- & -SGDD ⁶⁶⁴ CV- -YADD ⁵³⁵ TA- & -SGDD ⁶⁶⁶ CV- -YADD ²⁸⁴ TA- & -SGDD ⁴¹⁷ CV- -QGDD ⁶⁶⁷ M- & -LGDD ²⁶ A- -YG ³³² DDL-	By X-ray crystallography] [19] By SDM [35] [19] [19] By X-ray crystallography 32] By seqsimilarity This communication By SDM [29]
RdRps (EC 2.7.7.48) of	(-) Strand Viruses	
Ebola Ebola Influenza A Influenza B Influenza C Rabies Nipah Measles Mumps	-MGD ⁷⁴² NQC- & ,,, -TGD ³⁰⁵ NTK- & -QSSDD ⁴⁴⁶ FA- -TGD ³⁰⁵ NTK- & -QSSDD ⁴⁴⁵ FA- -TGD ³⁰⁷ NSK- & -QSSDD ⁴⁵¹ FV- -QGD ⁷²⁹ NQV- & -LESDD ¹⁵⁸⁹ NI-	By SDM [38] By SDM [39] By seq. similarity This communication

Possible metal binding sites arrived at by MSA and SDM; pol., polymerase; seq., sequence; EPRS, Electron Paramagnetic Resonance Spectroscopy; FD, Flow Dialysis. Palanivelu; IJBCRR, 29(10): 29-52, 2020; Article no.IJBCRR.64238




Fig. 9. Steps (1-4) involved in the proposed catalytic mechanism for CoV-2 RdRp

4. CONCLUSIONS

The MSA analysis of SARS and SARS-related CoV RdRps exhibited very high similarity among them. Though the MERS-CoV RdRp was deviating in many conserved motif regions, yet the active site regions and the catalytic amino acids are completely conserved. The RdRps of palm civet and SARS-CoV-1 exhibited very high similarity among themselves suggesting the possibility of palm civet as the possible intermediate. The universal metal binding motif in RdRps, viz. -GDD- and an additional metal binding motif -SDD- were found in all these SARS-CoV RNA polymerases. Active site regions and metal binding sites suggest that the RdRps should have evolved from DdDps (or vice-versa) rather than DdRps. The MSA analysis along with the X-ray crystallographic, cryo-EM and SDM data may enhance our understanding of the active site regions and catalytic mechanism of these viral RdRps and will help to assess not only the effectiveness of the existing drugs but also to design and develop new antiviral drugs for these enzymes.

ACKNOWLEDGMENTS

The author wishes to thank Dr. H. Shakila, Professor& Head, Department of Molecular Microbiology, School of Biotechnology, Madurai Kamaraj University, Madurai, for useful suggestions on the manuscript.

COMPETING INTERESTS

The author has declared that no competing interests exist.

REFERENCES

- 1. Kenneth KS Ng, Jamie J. Arnold, and Craig E. Cameron. Structure-function relationships among RNA-Dependent RNA polymerases. Curr Top Microbiol Immunol. 2008;320:137–156.
- 2. Wang Q, Wu J, Wang H, Gao Y, Liu Q, Mu A, Ji W, et al. Structural basis for RNA replication by the SARS-CoV-2 polymerase. Cell. 2020;182:417–428.
- Alberts B, Johnson J, Lewis J, Raff M, Roberts K, Walter P. Molecular biology of the cell. New York: Garland Science; 2003.
- Flint SJ, Enquist LW, Racaniello VR, Skalka AM. Principles of virology: molecular biology, pathogenesis, and control of animal viruses. Molecular

biology. Washington, DC: ASM Press; 2004.

- Elena SF, Sanjuan R. Adaptive value of high mutation rates of RNA viruses: Separating causes from consequences. J. Virol. 2005;79:11555–11558.
- Castro C, Arnold JJ, Cameron CE. Incorporation fidelity of the viral RNAdependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res. 2005;107:141–149.
- 7. Palanivelu P. Analyses of the Spike Proteins of Severe Acute Respiratory Syndrome-Related Coronaviruses. Microbiol Res J Int. 2020; 30:32-50.
- Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, Yuen KY. Genomic characterization of the 2019 novel humanpathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221-236.
- McBride R, Fielding BC. The role of severe acute respiratory syndrome (SARS)coronavirus accessory proteins in virus pathogenesis. Viruses. 2012;4:2902-2923.
- Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. In Maier HJ, Bickerton E, Britton P, editors. Coronaviruses. Met Mol Biol. 1282. Springer. 2015;1–23. DOI: 10.1007/978-1-4939-2438-7 1.
- 11. Thoms M, Buschauer R, Ameismeier M, Koepke L, Denk T, Hirschenberger M. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science. 2020;369:1249– 1255.
- 12. Wolff G, Limpens RWAL, Zevenhoven-Dobbe JC, Laugks U, Zheng S, de Jong AWM, Koning RI, et al. A molecular pore spans the double membrane of the coronavirus replication organelle. Science. 2020;369:1395-1398.
- Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. Antiviral Res. 2018;149:58–74.
- Sparrer KM, Gack MU. Intracellular detection of viral nucleic acids. Curr. Opin. Microbiol. 2015;26:1-9.
- 15. Bianchi M, Benvenuto D, Giovanetti M, Angeletti S, Ciccozzi M, Pascarella S. Sars-CoV-2 Envelope and Membrane Proteins: Structural differences Linked to Virus Characteristics? BioMed Res. Int. 2020;2020:1-6.

- 16. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265-269.
- Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D, Cramer P. Structure of replicating SARS-CoV-2 polymerase. bioRxiv preprint; 2020. Available:doi.org/10.1101/2020.04.27.0631 80.
- Subissi L, et al. SARS-CoV ORF1bencoded nonstructural proteins 12-16: replicative enzymes as antiviral targets. Antiviral Res. 2014;101:122-130. DOI: 10.1016/j.antiviral.2013.11.006.
- 19. Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, Wang T, et al. Structure of the RNAdependent RNA polymerase from COVID-19 virus. Science. 2020;368:779-782.
- 20. Zhang WF, Stephen P, Thériault JF, Wang R, Lin SX. Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks. J Phys Chem Lett. 2020;11:4430-4435.
- 21. Frediansyah A, Tiwari R Sharun K, Dhama K, Harapan H. Antivirals for COVID-19: A critical review. Clinical Epidemiology and Global Health; 2021. doi.org/10.1016/j.cegh.2020.07.006
- Palanivelu P. DNA polymerases An insight into their active sites and mechanism of action, In: Recent Advances in Biological Research. Sciencedomain International Book Publishers, UK. 2019;1: 1-39,

ISBN: 978-81-934224-4-1,

DOI:10.9734/bpi/rabr/v1,

- Palanivelu P. Single Subunit RNA Polymerases: An Insight into their Active Sites and Catalytic Mechanism, In: Advances and Trends in Biotechnology and Genetics. 2019;1:1-38. Sciencedomain International Book Publishers, UK. ISBN: 978-93-89246-59-9, DOI:10.9734/bpi/atbg/v1,
- 24. Palanivelu P. Multi-subunit RNA Polymerases of Bacteria - An insight into their active sites and catalytic mechanism. Indian J Sci Technol. 2018;11:1-37.
- 25. Palanivelu, P. Eukaryotic multi-subunit DNA dependent RNA Polymerases: An insight into their active sites and catalytic mechanism. In: Emerging Trends and Research in Biological Science. Sciencedomain International Book Publishers, UK. 2020;1:1-66.

ISBN: 978-93-89562-56-9, DOI: 10.9734/bpi/etrbs/v1,

- Palanivelu, P. Active sites of the multisubunit RNA polymerases of eubacteria and chloroplasts are similar in structure and function: Recent perspectives. In: Current Research Trends in Biological Science. Sciencedomain International Book Publishers, UK. 2020;2:26-61. ISBN: 978-93-90149-66-7, DOI: 10.9734/bpi/crtbs/v2,
- 27. Hansen JL, Long AM, Schultz SC. Structure of the RNA-dependent RNA polymerase of poliovirus. Structure. 1997; 5:1109-1127.
- Sangita V, Prasad BVLS, Selvarajan R. RNA dependent RNA polymerases: Insights from structure, function and evolution. Viruses. 2018;10:76-99.
- 29. Sankar S, Porter AG. Point mutations which drastically affect the polymerization activity of encephalomyocarditis virus RNA-dependent RNA polymerase correspond to the active site of *Escherichia coli*. DNA polymerase I. J Biol Chem. 1992; 267:10168–10176.
- 30. Jablonski SA, Luo M, Morrow CD. Enzymatic activity of poliovirus RNA polymerase mutants with single amino acid changes in the conserved YGDD amino acid motif. J Virol. 1991;6:4565-4572.
- 31. Inokuchi Y, Hirashima A. Interference with viral infection by RNA replicase deleted at the carboxy-terminal region. J. Virol. 1987; 61:3946-3949.
- Yap TL, Xu T, Chen YL, Malet H, Egloff MP, Canard B, Vasudevan SG, Lescar J. Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-Angstrom resolution. J Virol. 2007;81: 4753–4765.
- 33. Lehmann KC, Gulyaeva A, Zevenhoven-Dobbe JC, Janssen GMC, Ruben M, Overkleeft HS, van Veelen PA, Samborskiy DV, Kravchenko AA, Leontovich AM, et al.. Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerasecontaining protein of all nidoviruses. Nucleic Acids Res. 2015;43:8416–8434.
- Kostyuk SM, Dragan DL, Lyakhov VO, Rechinsky VL, Tunitskaya BK, Chernov SN, Kochetkov E. Mutants of T7 RNA polymerase that are able to synthesize both RNA and DNA. FEBS Letters. 1995; 369:165-168.

- 35. Imbert I, Guillemot JC, Bourhis JM, Bussetta C, Coutard B, Egloff MP, Ferron F. et al. A second, non-canonical RNAdependent RNA polymerase in SARS coronavirus. EMBO J. 2006;25:4933-4942.
- 36. te Velthuis AJW, van den Worm SH, Snijder EJ. The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension. Nucleic Acids Res. 2012;40:1737-17.
- Subissia L, Posthumab CC, Colleta A, Dobbeb JCZ, Gorbalenyab AE, Decrolya E, Snijderb EJ, Canarda B, Imberta I, One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc Natl Acad Sci (USA). 2014;E3900–E3909.
- Schmidt ML, Hoenen T. Characterization of the catalytic center of the Ebola virus L polymerase. PLoS Negl Trop Dis. 2017;11:1-14.
- Tchesnokov EP, Raeisimakiani P, Ngure M, Marchant D, Götte M. Recombinant RNAdependent RNA polymerase complex of ebola virus. Sci Rep. 2018;8:3970-3979.
- Zhang G, Campbell EA, Minakhin L, Richter C, Severinov K, Darst SA. Crystal structure of *Thermus aquaticus* core RNA polymerase at 3.3 Å resolution. Cell. 1999; 98:811-824.
- 41. Woody AY, Eaton SS, Osumi-Davis PA, Woody RW, Asp537 and Asp812 in bacteriophage T7 RNA polymerase as metal ion-binding sites studied by EPR, flow-dialysis, and transcription. Biochemistry. 1996;35:144-152.

© 2020 Palanivelu; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history: The peer review history for this paper can be accessed here: http://www.sdiarticle4.com/review-history/64238